Document:

<PAGE>

================================================================================

                     AMENDED AND RESTATED SECURITY AGREEMENT

                                       By

                          WOMEN FIRST HEALTHCARE, INC.,
                                   as Company,

                 THE GUARANTORS FROM TIME TO TIME PARTY HERETO,
                                 as Guarantors,

                                       and

                                 CIBC WMC INC.,
                               as Collateral Agent

                             ----------------------

                            Dated as of May 12, 2003

================================================================================
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                            Page
                                                                                            ----
<S>                                                                                         <C>
PREAMBLE................................................................................     1

RECITALS................................................................................     1

AGREEMENT...............................................................................     2

                                    ARTICLE I

                         DEFINITIONS AND INTERPRETATION

SECTION 1.1        Definitions..........................................................     2
SECTION 1.2        Interpretation.......................................................    15
SECTION 1.3        Resolution of Drafting Ambiguities...................................    15

                                   ARTICLE II

                    GRANT OF SECURITY AND SECURED OBLIGATIONS

SECTION 2.1        First Priority Security Interest.....................................    15
SECTION 2.2        Second Priority Security Interest....................................    17
SECTION 2.3        Preferred Stock Second Priority Security Interest....................    18
SECTION 2.4        INTENTIONALLY OMITTED................................................    19
SECTION 2.5        Security Interests...................................................    19
SECTION 2.6        No Release...........................................................    20

                                   ARTICLE III

                  PERFECTION; SUPPLEMENTS; FURTHER ASSURANCES;
                                USE OF COLLATERAL

SECTION 3.1        Delivery of Certificated Securities Collateral.......................    21
SECTION 3.2        Perfection of Uncertificated Securities Collateral...................    21
SECTION 3.3        Financing Statements and Other Filings; Maintenance of
                      Perfected Security Interest.......................................    21
SECTION 3.4        Other Actions........................................................    22
SECTION 3.5        Joinder of Additional Guarantors.....................................    26
SECTION 3.6        Use and Pledge of Collateral.........................................    26
</TABLE>

                                      -i-
<PAGE>
<TABLE>
<CAPTION>
                                                                                            Page
                                                                                            ----
<S>                                                                                         <C>
                                   ARTICLE IV

                    REPRESENTATIONS, WARRANTIES AND COVENANTS

SECTION 4.1        Title, Authority and Validity; Preservation of Corporate
                      Existence.........................................................    26
SECTION 4.2        Validity of Security Interests.......................................    27
SECTION 4.3        Limitation on Liens..................................................    27
SECTION 4.4        Other Financing Statements...........................................    27
SECTION 4.5        Chief Executive Office; Change of Name; Jurisdiction of
                      Organization......................................................    28
SECTION 4.6        Location of Inventory and Equipment..................................    28
SECTION 4.7        Condition and Maintenance of Equipment...............................    29
SECTION 4.8        Corporate Names; Prior Transactions..................................    29
SECTION 4.9        No Claims............................................................    29
SECTION 4.10       No Conflicts, Consents, etc..........................................    29
SECTION 4.11       Collateral...........................................................    30
SECTION 4.12       Insurance............................................................    30
SECTION 4.13       Payment of Taxes; Compliance with Laws; Contesting Liens;
                      Claims............................................................    30
SECTION 4.14       Access to Collateral, Books and Records; Other Information...........    31

                                    ARTICLE V

               CERTAIN PROVISIONS CONCERNING SECURITIES COLLATERAL

SECTION 5.1        Pledge of Additional Securities Collateral...........................    31
SECTION 5.2        Voting Rights; Distributions; etc....................................    31
SECTION 5.3        Operative Agreements.................................................    32
SECTION 5.4        Defaults, etc........................................................    33

                                   ARTICLE VI

                   CERTAIN PROVISIONS CONCERNING INTELLECTUAL
                               PROPERTY COLLATERAL

SECTION 6.1        Grant of License.....................................................    33
SECTION 6.2        Registrations........................................................    33
SECTION 6.3        No Violations or Proceedings.........................................    34
SECTION 6.4        Protection of Collateral Agent's Security............................    34
SECTION 6.5        After-Acquired Property..............................................    35
SECTION 6.6        Modifications........................................................    35
SECTION 6.7        Litigation...........................................................    35
</TABLE>

                                      -ii-
<PAGE>
<TABLE>
<CAPTION>
                                                                                            Page
                                                                                            ----
<S>                                                                                         <C>
                                    ARTICLE VII

                     CERTAIN PROVISIONS CONCERNING ACCOUNTS

SECTION 7.1        Special Representations and Warranties...............................    36
SECTION 7.2        Maintenance of Records...............................................    36
SECTION 7.3        Legend...............................................................    37
SECTION 7.4        Modification of Terms, etc...........................................    37
SECTION 7.5        Collection...........................................................    37

                                  ARTICLE VIII

                            TRANSFERS AND OTHER LIENS

SECTION 8.1        Transfers of and other Liens on Collateral...........................    37

                                   ARTICLE IX

                                    REMEDIES

SECTION 9.1        Remedies.............................................................    38
SECTION 9.2        Notice of Sale.......................................................    40
SECTION 9.3        Waiver of Notice and Claims..........................................    40
SECTION 9.4        Certain Sales of Collateral..........................................    40
SECTION 9.5        No Waiver; Cumulative Remedies.......................................    42
SECTION 9.6        Certain Additional Actions Regarding Intellectual Property...........    42

                                    ARTICLE X

                             APPLICATION OF PROCEEDS

                                   ARTICLE XI

                                  MISCELLANEOUS

SECTION 11.1       Concerning the Collateral Agent......................................    43
SECTION 11.2       Collateral Agent May Perform; Collateral Agent Appointed
                      Attorney-in-Fact..................................................    44
SECTION 11.3       Expenses.............................................................    44
SECTION 11.4       Indemnity............................................................    45
SECTION 11.5       Continuing Security Interests; Assignment............................    46
SECTION 11.6       Termination; Release.................................................    46
SECTION 11.7       Modification in Writing..............................................    46
</TABLE>

                                     -iii-
<PAGE>
<TABLE>
<CAPTION>
                                                                                            Page
                                                                                            ----
<S>                                                                                         <C>
SECTION 11.8       Notices..............................................................    46
SECTION 11.9       GOVERNING LAW........................................................    47
SECTION 11.10      CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF
                      JURY TRIAL........................................................    47
SECTION 11.11      Severability of Provisions...........................................    47
SECTION 11.12      Execution in Counterparts............................................    47
SECTION 11.13      Business Days........................................................    47
SECTION 11.14      No Credit for Payment of Taxes or Imposition.........................    48
SECTION 11.15      No Claims Against Collateral Agent...................................    48
SECTION 11.16      Obligations Absolute.................................................    48
</TABLE>

SIGNATURES

SCHEDULE 1.1(a)     Prior Liens on Pledged Collateral
SCHEDULE 1.1(b)     Prior Liens on Second Lien Collateral
SCHEDULE 4.10       Required Consents
SCHEDULE 6.3        Violations or Proceedings

EXHIBIT 1           Form of Issuer Acknowledgment
EXHIBIT 2(a)        Form of Control Agreement Concerning Deposit Accounts
EXHIBIT 2(b)        Form of Control Agreement Concerning Securities Accounts
EXHIBIT 3           Form of Bailee Letter
EXHIBIT 4           Form of Pledge Amendment
EXHIBIT 5           Form of Joinder Agreement

                                      -iv-
<PAGE>
                               SECURITY AGREEMENT

            AMENDED AND RESTATED SECURITY AGREEMENT (the "Agreement"), dated as
of May 12, 2003, made by WOMEN FIRST HEALTHCARE, INC., a Delaware corporation
having an office at 12220 El Camino Real, Suite 400, San Diego, California 92130
(the "Company"), and THE GUARANTORS FROM TIME TO TIME PARTY HERETO (the
"Guarantors"), as pledgors, assignors and debtors (the Company, together with
the Guarantors, in such capacities and together with any successors in such
capacities, the "Issuers" and each an "Issuer") in favor of CIBC WMC INC.,
having an office at C/O CIBC Capital Partners, 425 Lexington Avenue, New York,
New York 10017, in its capacity as Collateral Agent pursuant to the Securities
Purchase Agreement and Preferred Stock Purchase Agreement (each as hereinafter
defined), as pledgee, assignee and secured party (in such capacities and
together with any successors in such capacities, the "Collateral Agent").

                                 R E C I T A L S

            A. The Company and the Purchasers (as defined in the Securities
Purchase Agreement), in connection with the execution and delivery of that
certain security agreement dated as of June 25, 2002 (the "Original Security
Agreement"), entered into the Note and Warrant Purchase Agreement, dated as of
June 25, 2002, as amended by Amendment No. 1 to the Note and Warrant Purchase
Agreement, dated May 12, 2003 (as amended, amended and restated, supplemented or
otherwise modified from time to time, the "Securities Purchase Agreement"),
pursuant to which the Company issued its senior secured notes due 2005 (the
"Notes") in the aggregate principal amount of $28.0 million, together with
warrants to purchase common stock. It is contemplated that the Company may,
after the date hereof, issue Additional Notes (as defined in the Securities
Purchase Agreement; the Additional Notes, together with the Notes, the
"Securities") pursuant to the provisions of the Securities Purchase Agreement.

            B. The Company and the Purchasers (as defined in the Preferred Stock
Purchase Agreement), in connection with the execution and delivery of the
Original Security Agreement, entered into the Preferred Stock Purchase
Agreement, dated as of June 25, 2002 as amended by Amendment No. 1 to the
Preferred Stock Purchase Agreement, dated May 12, 2003 (as amended, amended and
restated, supplemented or otherwise modified from time to time, the "Preferred
Stock Purchase Agreement" and, together with the Securities Purchase Agreement,
the "Purchase Agreements"), pursuant to which the Company initially issued
Senior Convertible Redeemable Preferred Stock, Series A in the initial stated
value of $13.0 million which the Company is exchanging on the date hereof for
shares of Senior Convertible Redeemable Preferred Stock, Series B having an
initial stated value of $14.181 million (the "Preferred Stock").

            C. Each Guarantor has, pursuant to the Guarantee Agreement, dated
May 12, 2003, among other things, fully and unconditionally guaranteed the
obligations of the Company under the Securities Purchase Agreement.

            D. The Company, the Collateral Agent, the Guarantors and the
Purchasers have agreed to amend the Securities Purchase Agreement and the
Preferred Stock Purchase Agreement
<PAGE>
subject to the execution of this Agreement for the mutual benefit of the parties
hereto and the Secured Parties (as defined below).

            E. The Issuers are or, as to Collateral (as hereinafter defined)
acquired by such Issuer after the date hereof will be, the legal and/or
beneficial owner of the Collateral pledged by it hereunder.

            F. This Agreement is given by the Issuers in favor of the Collateral
Agent for the benefit of the Secured Parties (as hereinafter defined) to secure
the payment and performance of all of the Secured Obligations (as hereinafter
defined).

                               A G R E E M E N T :

            NOW THEREFORE, in consideration of the foregoing premises and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Issuers and the Collateral Agent hereby agree as follows:

                                   ARTICLE I

                         DEFINITIONS AND INTERPRETATION

SECTION 1.1    Definitions.

            (a) Unless otherwise defined herein, terms used herein that are
defined in the UCC shall have the meanings assigned to them in the UCC,
including the following terms which are capitalized herein:

            "Accounts"; "Bank"; "Chattel Paper"; "Commercial Tort Claim";
"Commodity Account"; "Commodity Intermediary"; "Documents"; "Electronic Chattel
Paper"; "Equipment"; "Financial Asset"; "Fixtures"; "Instruments" (as defined in
Article 9 rather than Article 3); "Inventory"; "Letter-of-Credit";
"Letter-of-Credit Right"; "Proceeds"; "Securities Account"; "Securities
Intermediary"; and "Tangible Chattel Paper".

            (b) Capitalized terms used but not otherwise defined herein that are
defined in the Purchase Agreements shall have the meanings given to them in the
Purchase Agreements, including the following terms:

            "Affiliate"; "Business Day"; "Capitalized Lease Obligations"; "Cash
Equivalents"; "Date of Closing"; "Debt"; "Event of Default"; "GAAP";
"Indebtedness"; "Lien"; "Person"; and "Purchase Money Indebtedness".

                                      -2-
<PAGE>
            (c) The following terms shall have the following meanings:

            "Acquisition Document Rights" shall mean, with respect to the
Company, collectively, all of the Company's rights, title and interest in, to
and under the Acquisition Documents including, without limitation, (i) all
rights and remedies relating to monetary damages, including indemnification
rights and remedies, and claims for damages or other relief pursuant to or in
respect of the Acquisition Documents, (ii) all rights and remedies relating to
monetary damages, including indemnification rights and remedies, and claims for
monetary damages under or in respect of the agreements, documents and
instruments referred to in the Acquisition Documents or related thereto and
(iii) all proceeds, collections, recoveries and rights of subrogation with
respect to the foregoing.

            "Acquisition Documents" shall mean, collectively, (i) that certain
Asset Purchase Agreement dated June 25, 2002, among the Company, Westwood Squibb
Colton Holdings Partnership, the Gillette Company and Bristol Myers Squibb
Company (the "Asset Purchase Agreement"); (ii) that certain Supply Agreement
dated June 25, 2002, among the Company, Westwood Squibb Colton Holdings
Partnership, the Gillette Company and Bristol Myers Squibb Company; and (iii)
that certain License Agreement dated June 25, 2002, among the Company, Westwood
Squibb Colton Holdings Partnership, the Gillette Company and Bristol Myers
Squibb Company; in each case, together with any and all documents, agreements
and other instruments then or at any time thereafter executed and/or delivered
in connection therewith or related thereto in each case as amended, amended and
restated, supplemented, extended, renewed, replaced or otherwise modified from
time to time.

            "Additional Pledged Interests" shall mean, collectively; with
respect to each Issuer, (i) all options, warrants, rights, agreements,
additional membership or partnership interests or other interests of whatever
class of any issuer of Initial Pledged Interests or any interest in any such
issuer, including, without limitation, all rights, privileges, authority and
powers of each Issuer relating to the equity or membership or partnership
interests in any such issuer or under the Operative Agreements of any such
issuer, from time to time acquired by such Issuer in any manner and (ii) all the
membership, partnership or other interests, as applicable, of each limited
liability company, partnership or other entity (other than a corporation)
hereafter acquired or formed and all options, warrants, rights, agreements,
additional membership or partnership interests or other interests of whatever
class of such limited liability company, partnership or other entity including,
without limitation, all rights, privileges, authority and powers of such Issuer
relating to such equity or membership or partnership interests or under the
Operative Agreements of such limited liability company, partnership or other
entity, from time to time acquired by such Issuer including the certificates,
instruments and agreements representing such additional interests and any and
all interest of such Issuer in the entries on the books of any financial
intermediary pertaining to such additional interests.

            "Additional Pledged Shares" shall mean, collectively, with respect
to each Issuer, (i) all options, warrants, rights, agreements, additional shares
of capital stock of whatever class of any issuer of the Initial Pledged Shares
or any interest in any such issuer, including, without limitation, all rights,
privileges, authority and powers of such Issuer relating to such additional

                                      -3-
<PAGE>
shares issued by any such issuer under the Operative Agreements of any such
issuer, from time to time acquired by such Issuer in any manner and (ii) all the
issued and outstanding shares of capital stock of each corporation hereafter
acquired or formed or shares required to be pledged under the Secured
Obligations and all options, warrants, rights, agreements or additional shares
of capital stock of whatever class of such corporation including, without
limitation, all rights, privileges, authority and powers of such Issuer relating
to such shares or under the Operative Agreements of such corporation, from time
to time acquired by such Issuer in any manner, in each case, including the
certificates representing such additional shares and any and all interest of
such Issuer in the entries on the books of any financial intermediary pertaining
to such additional shares.

            "Agreement" shall mean this Agreement, as amended, amended and
restated, supplemented or otherwise modified from time to time in accordance
with the provisions hereof.

            "Bailee Letters" shall have the meaning assigned to such term in
Section 3.4 hereof.

            "Bactrim" shall mean any product sold in connection with the Bactrim
trademark and having the active ingredients trimethoprim and sulfamethoxazole,
in all current and future presentations and formulations.

            "Business" shall mean the marketing and sale of pharmaceutical
products and similar products into the OB/GYN, dermatological or dental markets
and the sale of self-care products to midlife women through a mail-order catalog
and/or internet web site.

            "Certificate of Designation" shall mean the Certificate of
Designation of Preferences and Rights of the Senior Convertible Redeemable
Preferred Stock, Series B filed with the Secretary of the State of Delaware on
May 12, 2003.

            "Charges" shall mean any and all property and other taxes,
assessments and special assessments, levies, fees and all governmental charges
imposed upon or assessed against, and all claims (including, without limitation,
landlords', carriers', mechanics', workmen's, repairmen's, laborers',
materialmen's, suppliers' and warehousemen's Liens and other claims arising by
operation of law) against, all or any portion of the Collateral.

            "Collateral" shall mean, collectively, the Pledged Collateral and,
to the extent the Company receives the Wyeth Consent, the Second Lien
Collateral.

            "Collateral Account Funds" shall mean, collectively, the following
from time to time on deposit in a collateral account: all funds (including,
without limitation, all Trust Monies), investments (including, without
limitation, all Cash Equivalents) and all certificates and instruments from time
to time representing or evidencing such investments; all notes, certificates of
deposit, checks and other instruments from time to time hereafter delivered to
or otherwise possessed by the Collateral Agent for or on behalf of the Issuers
in substitution for, or in addition to, any or all of the Collateral; and all
interest, dividends, cash, instruments and other property

                                      -4-
<PAGE>
from time to time received, receivable or otherwise distributed in respect of or
in exchange for any or all of the items constituting Collateral.

            "Collateral Agent" shall have the meaning assigned to such term in
the Preamble of this Agreement.

            "Collateral Material Adverse Effect" shall mean, as of any date of
determination and whether individually or in the aggregate (a) any event,
circumstance, occurrence or condition which has caused or resulted in (or would
reasonably be expected to cause or result in) a material adverse effect on the
business or operations as presently conducted in connection with the Collateral;
(b) any event, circumstance, occurrence or condition which has caused or
resulted in (or would reasonably be expected to cause or result in) a material
adverse effect on the value or utility of the Collateral; or (c) subject to
Section 2.3 of this Agreement, any event, circumstance, occurrence or condition
which has caused or resulted in (or would reasonably expect to cause or result
in) a material adverse effect on the legality, priority or enforceability of the
Lien created by this Agreement or the rights and remedies of the Collateral
Agent hereunder.

            "Company" shall have the meaning assigned to such term in the
Preamble hereof.

            "Contested Liens" shall mean, collectively, any Liens incurred in
respect of any Charges to the extent that the amounts owing in respect thereof
are not yet delinquent or are being contested and otherwise comply with the
provisions of Section 4.13 hereof; provided, however, that such Liens shall in
all respects be subject and subordinate in priority to the Liens and security
interests created and evidenced by this Agreement, except if and to the extent
that the law or regulation creating, permitting or authorizing such Lien
provides that such Lien must be superior to the Liens and security interests
created and evidenced hereby.

            "Contracts" shall mean, collectively, with respect to each Issuer,
all sale, service, performance, equipment or property lease contracts,
agreements and grants and all other contracts, agreements or grants (in each
case, whether written or oral, or third party or intercompany), between such
Issuer and third parties, and all assignments, amendments, restatements,
supplements, extensions, renewals, replacements or modifications thereof.

            "Control" shall mean (i) in the case of each Deposit Account,
"control," as such term is defined in Section 9-104 of the UCC, (ii) in the case
of any Security Entitlement, "control," as such term is defined in Section 8-106
of the UCC and (iii) in the case of any Commodity Contract, "control," as such
term is defined in Section 9-106 of the UCC.

            "Control Agreement" shall mean an agreement substantially in the
form annexed hereto as Exhibit 2(a) with respect to Deposit Accounts or Exhibit
2(b) with respect to Securities Accounts or Commodities Accounts or such other
agreement in form and substance acceptable to the Collateral Agent.

            "Controlled Account" shall mean a Securities Account, Commodity
Contract or a Deposit Account with respect to which the Collateral Agent has
Control.

                                      -5-
<PAGE>
            "Copyrights" shall mean, collectively, with respect to each Issuer,
all copyrights (whether statutory or common law, whether established or
registered in the United States or any other country or any political
subdivision thereof whether registered or unregistered and whether published or
unpublished) and all copyright registrations and applications made by such
Issuer, in each case, whether now owned or hereafter created or acquired by or
assigned to such Issuer, including, without limitation, the copyrights,
registrations and applications listed in Schedule 15(b) annexed to the
Perfection Certificate, together with any and all (i) rights and privileges
arising under applicable law with respect to such Issuer's use of such
copyrights, (ii) reissues, renewals, continuations and extensions thereof, (iii)
income, fees, royalties, damages, claims and payments now or hereafter due
and/or payable with respect thereto, including, without limitation, damages and
payments for past, present or future infringements thereof, (iv) rights
corresponding thereto throughout the world and (v) rights to sue for past,
present or future infringements thereof.

            "Deposit Accounts" shall mean, collectively, with respect to each
Issuer, (i) all "deposit accounts" as such term is defined in the UCC and (ii)
all cash, funds, checks, notes and instruments from time to time on deposit in
any of the accounts described in clause (i) of this definition.

            "Destruction" shall mean any and all damage to, or loss or
destruction of, all or any portion of the Collateral.

            "Distributions" shall mean, collectively, all dividends, cash,
options, warrants, rights, instruments, distributions, returns of capital or
principal, income, interest, profits and other property, interests (debt or
equity) or proceeds, including as a result of a split, revision,
reclassification or other like change of the Pledged Securities, from time to
time received, receivable or otherwise distributed to such Issuer in respect of
or in exchange for any or all of the Pledged Securities or Intercompany Notes.

            "Equagesic" shall mean the product having the ingredients
memprobamate and aspirin and sold under the Equagesic trademark, in all current
and future presentations and formulations.

            "Esclim" shall mean the estrogen transdermal system sold under the
Esclim trademark in all current and future presentations and formulations.

            "Excluded Property" shall mean Special Property other than the
following:

            (a) Special Property described under clause (a) of the definition of
      Special Property to the extent that the applicable prohibition or
      restriction would be rendered unenforceable under Sections 9-406(f),
      9-407(a) or 9-408(a) of the UCC; and

            (b) any Proceeds, substitutions or replacements of any Special
      Property described under clauses (a) through (d) of the definition thereof
      (unless such Proceeds, substitutions or replacements would constitute
      Special Property).

                                      -6-
<PAGE>
            "FDA" shall mean the United States Food and Drug Administration, or
any successor entity.

            "General Intangibles" shall mean, collectively, with respect to each
Issuer, all "general intangibles," as such term is defined in the UCC, of such
Issuer relating to the Collateral and, in any event, shall include, without
limitation, (i) all of such Issuer's rights, title and interest in, to and under
all Insurance Policies and Contracts, (ii) all know-how and warranties relating
to any of the Collateral, (iii) any and all other rights, claims,
choses-in-action and causes of action of such Issuer against any other Person
and the benefits of any and all collateral or other security given by any other
Person in connection therewith, (iv) all guarantees, endorsements and
indemnifications on, or of, any of the Collateral, (v) all lists, books,
records, correspondence, ledgers, print-outs, files (whether in printed form or
stored electronically), tapes and other papers or materials containing
information relating to any of the Collateral, including, without limitation,
all customer or tenant lists, identification of suppliers, data, plans,
blueprints, specifications, designs, drawings, appraisals, recorded knowledge,
surveys, studies, engineering reports, test reports, manuals, standards,
processing standards, performance standards, catalogs, research data, computer
and automatic machinery software and programs and the like, field repair data,
accounting information pertaining to such Issuer's operations or any of the
Collateral and all media in which or on which any of the information or
knowledge or data or records may be recorded or stored and all computer programs
used for the compilation or printout of such information, knowledge, records or
data, (vi) all licenses, consents, permits, variances, certifications,
authorizations and approvals, however characterized, of any Governmental
Authority (or any Person acting on behalf of a Governmental Authority) now or
hereafter acquired or held by such Issuer pertaining to operations now or
hereafter conducted by such Issuer or any of the Collateral including, without
limitation, building permits, certificates of occupancy, environmental
certificates, industrial permits or licenses and certificates of operation and
(vii) all rights to reserves, deferred payments, deposits, refunds,
indemnification of claims to the extent the foregoing relate to any Collateral
and claims for tax or other refunds against any Governmental Authority relating
to any Collateral.

            "Goodwill" shall mean, collectively, with respect to each Issuer,
the goodwill connected with the Collateral including, without limitation, (i)
all goodwill connected with the use of and symbolized by any of the Intellectual
Property Collateral in which such Issuer has any interest and (ii) all know-how,
trade secrets, customer and supplier lists, proprietary information, inventions,
methods, procedures, formulae, descriptions, compositions, technical data,
drawings, specifications, name plates, catalogs, confidential information and
the right to limit the use or disclosure thereof by any Person, pricing and cost
information, business and marketing plans and proposals, consulting agreements,
engineering contracts and such other assets which relate to such goodwill.

            "Governmental Authority" shall mean any Federal, state, local,
foreign or other governmental, quasi-governmental or administrative (including
self-regulatory) body, instrumentality, department, agency, authority, board,
bureau, commission, office of any nature whatsoever or other subdivision
thereof, or any court, tribunal, administrative hearing body, arbitration panel

                                      -7-
<PAGE>
or other similar dispute-resolving body, whether now or hereafter in existence,
or any officer or official thereof, having jurisdiction over each Issuer or the
Collateral or any portion thereof.

            "Guarantor" shall have the meaning assigned to it in the Guarantee
Agreement.

            "Guarantee Agreement" shall mean the Senior Secured Guarantee
Agreement, dated as of the date hereof, by and among the Company, the Guarantors
and the Purchasers.

            "Indemnified Liabilities" shall have the meaning assigned to such
term in Section 11.4(i) hereof.

            "Indemnitees" shall have the meaning assigned to such term in
Section 11.4(i) hereof.

            "Initial Pledged Interests" shall mean all membership, partnership
or other equity interests (other than in a corporation), as applicable, of each
Issuer described in Schedule 12 annexed to the Perfection Certificate, together
with all rights, privileges, authority and powers of such Issuer in and to each
such issuer under the Operative Agreements of each such issuer, and the
certificates, instruments and agreements representing such membership,
partnership or other interests and any and all interest of such Issuer in the
entries on the books of any financial intermediary pertaining to such
membership, partnership or other interests.

            "Initial Pledged Shares" shall mean, collectively, the issued and
outstanding shares of capital stock of each Issuer described in Schedule 12
annexed to the Perfection Certificate together with all rights, privileges,
authority and powers of such Issuer in and to each such issuer under the
Operative Agreements of each such issuer, and the certificates, instruments and
agreements representing such shares of capital stock and any and all interest of
such Issuer in the entries on the books of any financial intermediary pertaining
to the Initial Pledged Shares.

            "Insurance Policies" shall mean the insurance policies and coverages
required to be maintained by each Issuer with respect to the Collateral pursuant
to Paragraph 5H of the Securities Purchase Agreement and all renewals and
extensions thereof.

            "Insurance Requirements" means, collectively, with respect to each
Issuer, all provisions of the Insurance Policies, all requirements of such
Issuer of any of the Insurance Policies and all orders, rules, regulations and
any other requirements of the National Board of Fire Underwriters (or any other
body exercising similar functions) binding upon such Issuer and applicable to
the Collateral or any use or condition thereof.

            "Intellectual Property Collateral" shall mean, collectively, the
Patents, Trademarks, Copyrights, Licenses, Know-How, Internet Names, Trade Dress
and Goodwill.

            "Intercompany Note" shall mean, if requested by the Collateral Agent
in writing, a Global Intercompany Note in form and substance acceptable to the
Collateral Agent.

                                      -8-
<PAGE>
            "Intercreditor Agreement" means that certain Intercreditor
Agreement, dated June 25, 2002, among the Purchaser and the Collateral Agent and
acknowledged by each Issuer.

            "Internet Names" shall mean all web addresses, domain names and
phone numbers held in the name of each Issuer or any of such Issuer's
subsidiaries and the applications and registrations therefor.

            "Investment Property" shall mean a security, whether certificated or
uncertificated, security entitlement, securities account, commodity contract or
commodity account, excluding (1) Securities Collateral and (2) any property
excluded from or not required to be pledged pursuant to the definition of
Pledged Shares, Pledged Interests or Successor Interests.

            "Joinder Agreement" shall mean the form of joinder agreement
attached hereto as Exhibit 5.

            "Know-How" shall mean any and all Manufacturing Know-How, product
specifications, processes, product designs, plans, trade secrets, ideas,
concepts, inventions, manufacturing, engineering and other manuals and drawings,
standard operating procedures, formulae, flow diagrams, chemical,
pharmacological, toxicological, pharmaceutical, physical, analytical, safety,
quality assurance, quality control and clinical data, technical information,
research records, and all other confidential or proprietary technical and
business information that is currently owned by each Issuer or is in the future
developed by or for such Issuer and used exclusively in the Business. For the
sake of clarity, none of the foregoing information shall be included in Know-How
to the extent that such information is covered by any claim of any Patent.

            "Licenses" shall mean, collectively, with respect to each Issuer,
all license and distribution agreements with, and covenants not to sue, any
other party with respect to any Patent, Trademark or Copyright, whether such
Issuer is a licensor or licensee, distributor or distributee under any such
license or distribution agreement, including, without limitation, the license
and distribution agreements listed in Schedules 15(a) and (b) annexed to the
Perfection Certificate, together with any and all (i) renewals, extensions,
supplements and continuations thereof, (ii) income, fees, royalties, damages,
claims and payments now and hereafter due and/or payable thereunder and with
respect thereto including, without limitation, damages and payments for past,
present or future infringements or violations thereof, (iii) rights to sue for
past, present and future infringements or violations thereof and (iv) other
rights to use, exploit or practice any or all of the Patents, Trademarks or
Copyrights.

            "Manufacturing Know-How" shall mean the percentages and
specifications of ingredients, the manufacturing processes, specifications,
technology, inventions, assays, quality control and testing procedures, know-how
and trade secrets owned by each Issuer and used exclusively to manufacture,
formulate, test and package the Products for sale, marketing and distribution.
For the sake of clarity, none of the foregoing information shall be included in
Know-How to the extent that such information is covered by any claim of any
Patent.

                                      -9-
<PAGE>
            "Marketing Materials" shall mean all marketing materials, marketing
research data, customer and sales information, product literature, promotional
materials and data, advertising and display materials and all training materials
in whatever medium (e.g., audio, visual or print) held in each Issuer's name and
exclusively related to the Business.

            "Material Intellectual Property" means Intellectual Property
Collateral owned by or in which each Issuer has any interest which is material
to its business.

            "Midrin" shall mean all formulations of the pharmaceutical product
sold under the registered trademark Midrin(R), in all current and future
presentations and formulations.

            "NDA" shall mean any new drug application filed pursuant to the
requirements of the FDA, as more fully defined in 21 C.F.R.Section314.5 et seq.,
and any equivalent application filed with any Governmental Authority.

            "Notes" shall have the meaning assigned to such term in Recital A
hereof.

            "Operative Agreement" shall mean (i) in the case of any limited
liability company or partnership or other non-corporate entity, any membership
or partnership agreement or other organizational agreement or document thereof
and (ii) in the case of any corporation, any charter or certificate of
incorporation and by-laws thereof.

            "Ortho-Est" shall mean the estropipate product packaged under the
name Ortho-Est(R), in all current and future presentations and formulations.

            "Patents" shall mean, collectively, with respect to each Issuer, all
patents issued or assigned to and all patent applications and registrations made
by such Issuer (whether established or registered or recorded in the United
States or any other country or any political subdivision thereof), including,
without limitation, those listed in Schedule 15(a) annexed to the Perfection
Certificate, together with any and all (i) rights and privileges arising under
applicable law with respect to such Issuer's use of any such patents, (ii)
inventions and improvements described and claimed therein, (iii) reissues,
divisions, continuations, renewals, extensions and continuations-in-part
thereof, (iv) income, fees, royalties, damages, claims and payments now or
hereafter due and/or payable thereunder and with respect thereto including,
without limitation, damages and payments for past, present or future
infringements thereof, (v) rights corresponding thereto throughout the world and
(vi) rights to sue for past, present or future infringements thereof.

            "Perfection Certificate" shall mean that certain Perfection
Certificate dated May 12, 2003, executed and delivered by each Issuer in favor
of the Collateral Agent and each other Perfection Certificate (which shall be in
form and substance reasonably acceptable to the Collateral Agent), executed and
delivered by an Issuer in favor of the Collateral Agent for the benefit of the
Secured Parties contemporaneously with the execution and delivery of each
Joinder Agreement executed in accordance with Section 3.5 hereof, in each case,
as the same may be amended, amended and restated, supplemented or otherwise
modified from time to time upon the request of the Collateral Agent.

                                      -10-
<PAGE>
            "Permitted Collateral Liens" shall have the meaning assigned to such
term in Section 4.3 hereof.

            "Pledged Collateral" shall have the meaning set forth in Section
2.1.

            "Pledged Interests" shall mean, collectively, the Initial Pledged
Interests and the Additional Pledged Interests; provided, however, that to the
extent applicable, such Issuer shall not be required to pledge (i) any interest
possessing more than 65% of the voting power or control of all classes of
interests entitled to vote of any Subsidiary which is a first-tier controlled
foreign corporation (as defined in Section 957(a) of the Tax Code) or (ii) the
interests of any Subsidiary otherwise required to be pledged pursuant to this
Agreement to the extent that such pledge would constitute an investment of
earnings in United States property under Section 956 (or a successor provision)
of the Tax Code, which investment would trigger an increase in the gross income
of a United States shareholder of such Subsidiary pursuant to Section 951 (or a
successor provision) of the Tax Code.

            "Pledged Securities" shall mean, collectively, the Pledged
Interests, the Pledged Shares and the Successor Interests.

            "Pledged Shares" shall mean, collectively, the Initial Pledged
Shares and the Additional Pledged Shares; provided, however, that each Issuer
shall not be required to pledge (i) shares possessing more than 65% of the
voting power of all classes of capital stock entitled to vote of any Subsidiary
which is a first tier controlled foreign corporation (as defined in Section
957(a) of the Tax Code) or (ii) the shares of stock of any Subsidiary otherwise
required to be pledged pursuant to this Agreement to the extent that such pledge
would constitute an investment of earnings in United States property under
Section 956 (or a successor provision) of the Tax Code, which investment would
trigger an increase in the gross income of a United States shareholder of such
Subsidiary pursuant to Section 951 (or a successor provision) of the Tax Code.

            "Preferred Stock Purchase Agreement" shall have the meaning assigned
to such term in Recital B hereof.

            "Preferred Stock" shall have the meaning assigned to such term in
Recital B hereof.

            "Prior Liens" shall mean, collectively, the Liens identified in
Schedules 1.1(a) and 1.1(b) attached hereto relating to the items of Collateral
identified in such Schedules.

            "Product Registrations" shall mean the NDAs (including any Marketing
Authorization Approvals) and comparable regulatory filings and approvals for the
Products held in an Issuer's name.

            "Products" shall mean Vaniqa, Bactrim, Ortho-Est, Synalgos,
Equagesic, and any future pharmaceutical products (excluding the Special
Property) acquired by the Company.

                                      -11-
<PAGE>
            "Prudent Operator" shall mean the standard of care taken by a
prudent operator of property and assets similar in use and configuration to the
Collateral, as the case may be, and located in the locality where the
Collateral, as the case may be, is located.

            "Purchase Agreements" shall have the meaning assigned to such term
in Recital B hereof.

            "Regulatory Documentation" shall mean all (a) regulatory filings and
supporting documents, chemistry, manufacturing and controls data and
documentation, preclinical and clinical studies and tests, (b) records
maintained under record keeping or reporting requirements of the FDA, or any
other Governmental Authority including without limitation the drug master file
and Investigational New Drug application, and (c) the complete complaint,
adverse event and medical inquiry filings with respect to the Products; in each
case held in such Issuer's name and in each case exclusively related to the
Business, including the Product Registrations.

            "Requirements of Law" shall mean, collectively, any and all
requirements of any Governmental Authority including, without limitation, any
and all laws, ordinances, rules, regulations or similar statutes or case law.

            "Second Lien Collateral" shall mean all rights and interests held by
the Company related to Synalgos, Wygesic and Equagesic.

            "Secured Obligations" shall mean all obligations (whether or not
constituting future advances, obligatory or otherwise) of each Issuer from time
to time arising under or in respect of this Agreement, the Purchase Agreements,
the Securities, the Preferred Stock, the Certificate of Designation, the
Guarantee Agreement and the other Security Documents (including, without
limitation, the obligations to pay principal, interest and all other charges,
fees, expenses, commissions, reimbursements, premiums, indemnities and other
payments related to or in respect of the obligations contained in this
Agreement, the Purchase Agreements, the Securities, the Preferred Stock, the
Certificate of Designation and the other Security Documents), in each case
whether (i) such obligations are direct or indirect, secured or unsecured, joint
or several, absolute or contingent, due or to become due whether at stated
maturity, by acceleration or otherwise, (ii) arising in the regular course of
business or otherwise, (iii) for payment or performance and/or (iv) now existing
or hereafter arising (including, without limitation, interest and other
obligations arising or accruing after the commencement of any bankruptcy,
insolvency, reorganization or similar proceeding with respect to such Issuer or
any other Person, or which would have arisen or accrued but for the commencement
of such proceeding, even if such obligation or the claim therefor is not
enforceable or allowable in such proceeding).

            "Secured Parties" shall mean, collectively, the Collateral Agent and
the holders of the Securities and the Preferred Stock.

            "Securities" shall have the meaning assigned to such term in Recital
A hereof.

                                      -12-
<PAGE>
            "Securities Collateral" shall mean, collectively, the Pledged
Securities, the Intercompany Note, and the Distributions.

            "Securities Purchase Agreement" shall have the meaning assigned to
such term in Recital A hereof.

            "Security Documents" means this Agreement, the Perfection
Certificate, and each other security document or pledge agreement required by
applicable law to grant a valid, perfected Lien on and security interest in the
Collateral, and all UCC or other financing statements or instruments of
perfection required by this Agreement and the Acquisition Documents and any
other document or instrument utilized to pledge any Property of whatever kind or
nature as collateral for the Debt.

            "Special Property" shall mean:

            (a) any contract, permit, lease or license held by any Issuer that
      validly prohibits or restricts the creation by such Issuer of a security
      interest therein;

            (b) any permit, lease or license held by any Issuer to the extent
      that any Requirement of Law applicable thereto prohibits the creation of a
      security interest therein;

            (c) Equipment owned by any Issuer on the date hereof or hereafter
      acquired that is subject to a Lien securing a Purchase Money Indebtedness
      or Capitalized Lease Obligations permitted to be incurred pursuant to the
      provisions of the Purchase Agreements if the contract or other agreement
      in which such Lien is granted (or the documentation providing for such
      Purchase Money Indebtedness or Capitalized Lease Obligation) validly
      prohibits the creation of any other Lien on such Equipment;

            (d) any property that on the date hereof is subject to a valid and
      enforceable "negative pledge clause" or other agreement that prohibits the
      grant of a security interest therein; and

            (e) all rights and interests held exclusively in Esclim and/or
      Midrin.

provided, however, that in each case described in clauses (a), (b) and (c) of
this definition, such property shall constitute "Special Property" only to the
extent and for so long as such permit, lease, license, contract or other
agreement or Requirement of Law applicable thereto, validly prohibits the
creation of a Lien on such property in favor of the Collateral Agent and, upon
the termination of such prohibition (howsoever occurring), such property shall
cease to constitute "Special Property".

            "Subordinated Liens" shall have the meaning assigned to such term in
Section 4.3 hereof.

            "Successor Interests" shall mean, collectively, with respect to each
Issuer, all shares of each class of the capital stock of the successor
corporation or interests or certificates of

                                      -13-
<PAGE>
the successor limited liability company, partnership or other entity owned by
such Issuer (unless such successor is the Issuer itself) formed by or resulting
from any consolidation or merger in which any Person listed in Schedule 1(a)
annexed to the Perfection Certificate is not the surviving entity; provided,
however, that the pledge of the Successor Interests affected hereby shall in no
event affect the obligations of each Issuer under any provision prohibiting such
action hereunder or under the Purchase Agreements.

            "Synalgos" shall mean the pharmaceutical product sold under the name
Synalgos(R) and containing drocode (digydrocodeine) bitartrate, aspirin and
caffeine, in all current and future presentations and formulations.

            "Taking" shall mean any taking of the Collateral or any portion
thereof, in or by condemnation or other eminent domain proceedings pursuant to
any law, general or special, or by reason of the temporary requisition of the
use of the Collateral or any portion thereof, by any Governmental Authority,
civil or military.

            "Tax Code" shall mean the Internal Revenue Code of 1986, as amended
from time to time.

            "Trade Dress" shall mean the trade dress and packaging, including
without limitation the registered trade dress held in any Issuer's name and in
exclusively used in the Business.

            "Trademarks" shall mean, collectively, with respect to each Issuer,
all trademarks (including service marks), logos, slogans, logos, certification
marks, trade dress, uniform resource locations (URL's), domain names, corporate
names and trade names, whether registered or unregistered, owned by or assigned
to such Issuer relating to the Collateral and all registrations and applications
for the foregoing (whether statutory or common law and whether established or
registered in the United States or any other Country or any political
subdivision thereof), including, without limitation, the registrations and
applications listed in Schedule 15(a) annexed to the Perfection Certificate,
together with any and all (i) rights and privileges arising under applicable law
with respect to such Issuer's use of any such trademarks, (ii) reissues,
continuations, extensions and renewals thereof, (iii) income, fees, royalties,
damages and payments now and hereafter due and/or payable thereunder and with
respect thereto, including, without limitation, damages, claims and payments for
past, present or future infringements thereof, (iv) rights corresponding thereto
throughout the world and (v) rights to sue for past, present and future
infringements thereof.

            "UCC" shall mean the Uniform Commercial Code as in effect on the
date hereof in the State of New York; provided, however, that if by reason of
mandatory provisions of law, any or all of the attachment, perfection or
priority of the Collateral Agent's and the Secured Parties' security interest in
any item or portion of the Collateral is governed by the Uniform Commercial Code
as in effect in a jurisdiction other than the State of New York, the term "UCC"
shall mean the Uniform Commercial Code as in effect on the date hereof in such
other jurisdiction for purposes of the provisions hereof relating to such
attachment, perfection or priority and for purposes of definitions relating to
such provisions.

                                      -14-
<PAGE>
            "Vaniqa" shall mean VANIQA(TM) (eflornithine hydrochloride) Cream
13.9%, in all current and future presentations and formulations.

            "Vaniqa Collateral" shall have the meaning set forth in Section 2.3.

            "Wygesic" shall mean the product having the ingredients
(propoxyphene HCl and acetaminophen) and sold under the Wygesic trademark, in
all current and future presentations and formulations.

            "Wyeth" shall mean Wyeth, a Delaware corporation.

            "Wyeth Consent" shall mean Wyeth's written consent, delivered to the
Company, consenting to the granting of a security interest in the Second Lien
Collateral by the Issuers to the Collateral Agent for the benefit of the holders
of the Securities.

            SECTION 1.2 Interpretation. The rules of construction set forth in
Paragraph 10 of the Securities Purchase Agreements shall be applicable to this
Agreement.

            SECTION 1.3 Resolution of Drafting Ambiguities. Each Issuer
acknowledges and agrees that it was represented by counsel in connection with
the execution and delivery hereof, that it and its counsel reviewed and
participated in the preparation and negotiation hereof and that any rule of
construction to the effect that ambiguities are to be resolved against the
drafting party (i.e., the Collateral Agent) shall not be employed in the
interpretation hereof.

                                   ARTICLE II

                    GRANT OF SECURITY AND SECURED OBLIGATIONS

            SECTION 2.1 First Priority Security Interest. As collateral security
for the payment and performance in full of all the Secured Obligations relating
to the Securities, each Issuer hereby pledges and grants to the Collateral Agent
for its benefit and for the benefit of the holders of the Securities, a first
priority lien on and security interest in and to all of the right, title and
interest of such Issuer in, to and under the following property, wherever
located, whether now existing or hereafter arising or acquired from time to time
(collectively, the "Pledged Collateral"):

         (i)      all Accounts,

         (ii)     all Equipment, Goods, Inventory and Fixtures;

         (iii)    all Documents, Instruments and Chattel Paper;

         (iv)     all Letter-of Credit Rights;

                                      -15-
<PAGE>
         (v)      all Securities Collateral;

         (vi)     all Investment Property;

         (vii)    all Intellectual Property Collateral;

         (viii)   the Commercial Tort Claims described on Schedule 16 to the
                  Perfection Certificate;

         (ix)     the Acquisition Documents and the Acquisition Document Rights;

         (x)      all General Intangibles;

         (xi)     all Deposit Accounts;

         (xii)    all Supporting Obligations;

         (xiii)   all books and records;

         (xiv)    all Marketing Materials;

         (xv)     all Regulatory Documentation;

         (xvi)    to the extent not covered by clauses (i) through (xv) of this
                  sentence, all other personal property of such Issuer, whether
                  tangible or intangible; and

         (xvii)   all Proceeds and products of each of the foregoing and all
                  accessions to, substitutions and replacements for, and profits
                  and products of, each of the foregoing, any and all proceeds
                  of any insurance, indemnity, warranty or guaranty payable to
                  such Issuer from time to time with respect to any of the
                  foregoing.

            Notwithstanding anything to the contrary contained in clauses (i)
through (xvii) above, the security interests created by this Agreement shall not
extend to any Excluded Property, and the term "Pledged Collateral" shall not
include any Excluded Property or any Second Lien Collateral and (i) each Issuer
shall from time to time at the request of the Collateral Agent give written
notice to the Collateral Agent identifying in reasonable detail the Special
Property (and stating in such notice that such Special Property constitutes
"Excluded Property") and shall provide to the Collateral Agent such other
information regarding the Special Property as the Collateral Agent may
reasonably request and (ii) from and after the Date of Closing, no Issuer shall
permit to become effective in any document creating, governing or providing for
any permit, lease or license, a provision that would prohibit the creation of a
Lien on such permit, lease or license in favor of the Collateral Agent unless
such Issuer believes, in its reasonable judgment, that such prohibition is usual
and customary in transactions of such type.

                                      -16-
<PAGE>
            SECTION 2.2 Second Priority Security Interest. Subject to the last
paragraph of this Section 2.2, as collateral security for the payment and
performance in full of all the Secured Obligations relating to the Securities,
each Issuer hereby pledges and grants to the Collateral Agent for its benefit
and for the benefit of the holders of the Securities, a second priority lien
(subject only to the existing liens held by Wyeth in the Second Lien Collateral)
on and security interest in and to all of the right, title and interest of such
Issuer in, to and under the Second Lien Collateral, wherever located, whether
now existing or hereafter arising or acquired from time to time, which Second
Lien Collateral includes, but is not limited to:

         (i)      all Intellectual Property Collateral exclusively related to or
                  used only in connection with the Second Lien Collateral;

         (ii)     the Commercial Tort Claims described on Schedule 16 to the
                  Perfection Certificate exclusively related to or used only in
                  connection with the Second Lien Collateral;

         (iii)    all General Intangibles exclusively related to or used only in
                  connection with the Second Lien Collateral;

         (iv)     all books and records exclusively related to or used only in
                  connection with the Second Lien Collateral;

         (v)      all Marketing Materials exclusively related to or used only in
                  connection with the Second Lien Collateral;

         (vi)     all Regulatory Documentation exclusively related to or used
                  only in connection with the Second Lien Collateral;

         (vii)    to the extent not covered by clauses (i) through (vi) of this
                  sentence all other personal property of such Issuer
                  exclusively related to or used only in connection with the
                  Second Lien Collateral, whether tangible or intangible; and

         (viii)   all Proceeds and products of each of the foregoing and all
                  accessions to, substitutions and replacements for, and profits
                  and products of, each of the foregoing, any and all proceeds
                  of any insurance, indemnity, warranty or guaranty payable to
                  such Issuer from time to time with respect to any of the
                  foregoing.

            Notwithstanding anything to the contrary contained in clauses (i)
through (viii) above, the security interests created by this Agreement shall not
extend to any Excluded Property, and the term "Second Lien Collateral" shall not
include any Excluded Property or any Pledged Collateral and (i) each Issuer
shall from time to time at the request of the Collateral Agent give written
notice to the Collateral Agent identifying in reasonable detail the Special
Property (and stating in such notice that such Special Property constitutes
"Excluded Property")

                                      -17-
<PAGE>
and shall provide to the Collateral Agent such other information regarding the
Special Property as the Collateral Agent may reasonably request and (ii) from
and after the Date of Closing, no Issuer shall permit to become effective in any
document creating, governing or providing for any permit, lease or license, a
provision that would prohibit the creation of a Lien on such permit, lease or
license in favor of the Collateral Agent unless such Issuer believes, in its
reasonable judgment, that such prohibition is usual and customary in
transactions of such type.

            Notwithstanding anything herein to the contrary, no Issuer shall be
obligated to grant a security interest or take any related action with respect
to the Second Lien Collateral until the Company receives the Wyeth Consent,
which consent the Company will use its best efforts to obtain. Upon receipt of
the Wyeth Consent, all provisions hereof shall be operative with no further
action taken by the parties hereto.

            SECTION 2.3 Preferred Stock Second Priority Security Interest. As
collateral security for the payment and performance in full of all the Secured
Obligations relating to the Preferred Stock, each Issuer hereby pledges and
grants to the Collateral Agent for its benefit and for the benefit of the
holders of the Preferred Stock, a second priority lien on and security interest
in and to all of the right, title and interest of such Issuer in, to and under
the Pledged Collateral to the extent, and only to the extent it relates
exclusively to Vaniqa, wherever located, whether now existing or hereafter
arising or acquired from time to time (collectively, the "Vaniqa Collateral"):

         (i)      all Accounts relating exclusively to Vaniqa;

         (ii)     all Equipment, Goods, Inventory and Fixtures relating
                  exclusively to Vaniqa;

         (iii)    all Documents, Instruments and Chattel Paper relating
                  exclusively to Vaniqa;

         (iv)     all Intellectual Property Collateral relating exclusively to
                  Vaniqa;

         (v)      the Commercial Tort Claims described on Schedule 16 to the
                  Perfection Certificate relating exclusively to Vaniqa;

         (vi)     all General Intangibles relating exclusively to Vaniqa
                  (including, without limitation, rights arising under common
                  law, statutes, or regulations, new drug applications and
                  modifications thereof);

         (vii)    the Acquisition Documents and Acquisition Document Rights;

         (viii)   all books and records relating exclusively to Vaniqa;

         (ix)     all Marketing Materials relating exclusively to Vaniqa;

         (x)      all Regulatory Documentation relating exclusively to Vaniqa;

                                      -18-
<PAGE>
         (xi)     to the extent not covered by clauses (i) through (x) of this
                  sentence, all other personal property of such Issuer relating
                  exclusively to Vaniqa, whether tangible or intangible; and

         (xii)    all Proceeds and products of each of the foregoing and all
                  accessions to, substitutions and replacements for, and profits
                  and products of, each of the foregoing, any and all proceeds
                  of any insurance, indemnity, warranty or guaranty payable to
                  such Issuer from time to time with respect to any of the
                  foregoing.

            Notwithstanding anything to the contrary contained in clauses (i)
through (xii) above, the security interests created by this Agreement shall not
extend to any Excluded Property, and the term "Vaniqa Collateral" shall not
include any Excluded Property, any other Pledged Collateral or any Second Lien
Collateral and (i) each Issuer shall from time to time at the request of the
Collateral Agent give written notice to the Collateral Agent identifying in
reasonable detail the Special Property (and stating in such notice that such
Special Property constitutes "Excluded Property") and shall provide to the
Collateral Agent such other information regarding the Special Property as the
Collateral Agent may reasonably request and (ii) from and after the Date of
Closing, no Issuer shall permit to become effective in any document creating,
governing or providing for any permit, lease or license, a provision that would
prohibit the creation of a Lien on such permit, lease or license in favor of the
Collateral Agent unless such Issuer believes, in its reasonable judgment, that
such prohibition is usual and customary in transactions of such type.
Notwithstanding the foregoing, (i) no representation or warranty is made by any
Issuer in this Agreement, with respect to the validity or enforceability of this
Section 2.3 with respect to the rights, if any, of the Secured Parties under
this Section 2.3, including with respect the creation or perfection of a
security interest, and the relative priority of any such security interest, or
the effect of the federal Bankruptcy Code and comparable provisions of state
law, and other applicable antifraud laws, securities laws, usury laws or public
policy considerations on the rights, if any, of the Secured Parties under this
Section 2.3; and (ii) no Issuer shall be held accountable for any failure to
create, perfect or maintain a security interest pursuant to this Section 2.3 by
reason of the foregoing; however, provided further, no Issuer shall, and shall
not permit any of its subsidiaries to, directly or indirectly, challenge the
enforceability, validity or perfection of the security interest created pursuant
to this Section 2.3 for the benefit of the Collateral Agent for the benefit of
the Secured Parties, or their transferees or assigns, on the Collateral, except
in the context of (i) any derivative actions brought on behalf of such Issuer
and (ii) proceedings under the Federal Bankruptcy Code or similar state
proceedings, to the extent required by law.

            SECTION 2.4 INTENTIONALLY OMITTED.

            SECTION 2.5 Security Interests(a). (a) Each Issuer hereby
irrevocably authorizes the Collateral Agent at any time and from time to time to
file in any relevant jurisdiction any initial financing statements (including
fixture filings) and amendments thereto that contain the information required by
Article 9 of the Uniform Commercial Code of each applicable jurisdiction for the
filing of any financing statement or amendment relating to the Collateral,
including, without limitation, whether such Issuer is an organization, the type
of organization and

                                      -19-
<PAGE>
any organizational identification number issued to such Issuer. Each Issuer
agrees to provide all information described in the immediately preceding
sentence to the Collateral Agent promptly upon request.

            (b) Each Issuer hereby ratifies its authorization for the Collateral
Agent to file in any relevant jurisdiction any initial financing statements or
amendments thereto relating to the Collateral if filed prior to the date hereof.

            (c) Each Issuer hereby further authorizes the Collateral Agent to
file filings with the United States Patent and Trademark Office or United States
Copyright Office (or any successor office or any similar office in any other
country) or other documents for the purpose of perfecting, confirming,
continuing, enforcing or protecting the security interests granted by such
Issuer hereunder, without the signature of such Issuer, and naming such Issuer,
as debtor, and the Collateral Agent, as secured party.

            (d) Collateral Agent hereby agrees not to deliver to any bank,
securities intermediary or other applicable financial institution any notice of
sole control or entitlement order with respect to any Deposit Account or
Securities Account governed by any Control Agreement unless an Event of Default
has occurred and is continuing. With respect to the financing statements filed
by the Collateral Agent with respect to the security interests granted pursuant
to Sections 2.1 and 2.2 of this Agreement, each Issuer authorizes such financing
statements to provide that they cover "all assets" or "all personal property" in
accordance with Section 9-504 of the New York UCC.

            SECTION 2.6 No Release. Nothing set forth in this Agreement shall
relieve such Issuer from the performance of any term, covenant, condition or
agreement on such Issuer's part to be performed or observed under or in respect
of any of the Collateral or from any liability to any Person under or in respect
of any of the Collateral or shall impose any obligation on the Collateral Agent
or any other Secured Party to perform or observe any such term, covenant,
condition or agreement on such Issuer's part to be so performed or observed or
shall impose any liability on the Collateral Agent or any other Secured Party
for any act or omission on the part of such Issuer relating thereto or for any
breach of any representation or warranty on the part of such Issuer contained in
this Agreement, the Purchase Agreements, the Securities, the Preferred Stock or
the other Security Documents, or under or in respect of the Collateral or made
in connection herewith or therewith. The obligations of each Issuer contained in
this Section 2.6 shall survive the termination hereof and the discharge of each
Issuer's other obligations under this Agreement and the Purchase Agreements, the
Securities, the Preferred Stock, the Certificate of Designation and the other
Security Documents.

                                      -20-

<PAGE>
                                   ARTICLE III

                  PERFECTION; SUPPLEMENTS; FURTHER ASSURANCES;
                                USE OF COLLATERAL

            SECTION 3.1 Delivery of Certificated Securities Collateral. All
certificates, agreements or instruments representing or evidencing the
Securities Collateral in existence on the date hereof have been delivered to the
Collateral Agent in suitable form for transfer by delivery or accompanied by
duly executed instruments of transfer or assignment in blank. Each Issuer hereby
agrees that all certificates, agreements or instruments representing or
evidencing Securities Collateral acquired by such Issuer after the date hereof,
shall immediately upon receipt thereof by such Issuer be delivered to and held
by or on behalf of the Collateral Agent pursuant hereto. All certificated
Securities Collateral shall be in suitable form for transfer by delivery or
shall be accompanied by duly executed instruments of transfer or assignment in
blank, all in form and substance reasonably satisfactory to the Collateral
Agent. The Collateral Agent shall have the right, at any time upon the
occurrence and during the continuance of any Event of Default, to endorse,
assign or otherwise transfer to or to register in the name of the Collateral
Agent or any of its nominees or endorse for negotiation any or all of the
Securities Collateral, without any indication that such Securities Collateral is
subject to the security interest hereunder. In addition, the Collateral Agent
shall have the right at any time to exchange certificates representing or
evidencing Securities Collateral for certificates of smaller or larger
denominations.

            SECTION 3.2 Perfection of Uncertificated Securities Collateral. Each
Issuer represents and warrants that upon the filing of the financing statements
listed on Schedule 6 of the Perfection Certificate the Collateral Agent has a
perfected first priority security interest in all uncertificated Pledged
Securities pledged by it hereunder that are in existence on the date hereof.
Each Issuer hereby agrees that if any issuer of Pledged Securities is organized
in a jurisdiction which does not permit the use of certificates to evidence
equity ownership, or if any of the Pledged Securities are at any time not
evidenced by certificates of ownership, then such Issuer shall, to the extent
permitted by applicable law, record such pledge on the equityholder register or
books of the issuer, cause the issuer to execute and deliver to the Collateral
Agent an acknowledgment of the pledge of such Pledged Securities substantially
in the form of Exhibit 1 annexed hereto, execute any customary pledge forms or
other documents necessary or appropriate to complete the pledge and give the
Collateral Agent the right to transfer such Pledged Securities under the terms
hereof and provide to the Collateral Agent an opinion of counsel, in form and
substance reasonably satisfactory to the Collateral Agent, confirming such
pledge and perfection thereof.

            SECTION 3.3 Financing Statements and Other Filings; Maintenance of
Perfected Security Interest. The only filings, registrations and recordings
necessary and appropriate to create, preserve, protect, publish notice of and
perfect the security interests granted by each Issuer to the Collateral Agent
(for the benefit of the Secured Parties) pursuant to this Agreement in respect
of the Collateral are listed in Schedule 7 of the Perfection Certificate. All
such filings, registrations and recordings have been delivered to the Collateral
Agent in completed and, to the

                                      -21-
<PAGE>
extent necessary or appropriate, duly executed form for filing in each
governmental, municipal or other office specified in Schedule 7 of the
Perfection Certificate and shall be filed, registered and recorded immediately
after the date thereof. Each Issuer agrees that at the sole cost and expense of
the Issuers, (i) such Issuer will maintain the security interests created by
this Agreement in the Collateral as perfected security interests having at least
the priority required hereunder and shall defend such security interests against
the claims and demands of all Persons, (ii) such Issuer will furnish to the
Collateral Agent from time to time statements and schedules further identifying
and describing the Collateral and such other reports in connection with the
Collateral as the Collateral Agent may reasonably request, all in reasonable
detail and (iii) at any time and from time to time, upon the written request of
the Collateral Agent, such Issuer will promptly and duly execute and deliver,
and have recorded, such further instruments and documents and take such further
action as the Collateral Agent may reasonably request for the purpose of
obtaining or preserving the full benefits of this Agreement and of the rights
and powers herein granted, including the filing of any financing or continuation
statement under the UCC (or other similar laws) in effect in any jurisdiction
with respect to the security interests created hereby and the execution and
delivery of Control Agreements.

            SECTION 3.4 Other Actions. In order to further insure the
attachment, perfection and priority of, and the ability of the Collateral Agent
to enforce, the Collateral Agent's security interests in the Collateral, each
Issuer agrees, in each case at such Issuer's own expense, to take the following
actions with respect to the following Collateral:

            (a) Instruments and Tangible Chattel Paper. As of the date hereof,
      each Issuer hereby represents and warrants that no amount individually or
      in the aggregate in excess of $100,000 payable under or in connection with
      any of the Collateral is evidenced by any Instrument or Tangible Chattel
      Paper other than such Instruments and Tangible Chattel Paper listed in
      Schedule 13 of the Perfection Certificate. If any amount individually or
      in the aggregate in excess of $100,000 payable under or in connection with
      any of the Collateral shall be evidenced by any Instrument or Tangible
      Chattel Paper, the Issuer acquiring such Instrument or Tangible Chattel
      Paper shall forthwith endorse, assign and deliver the same to the
      Collateral Agent, accompanied by such instruments of transfer or
      assignment duly executed in blank as the Collateral Agent may from time to
      time specify; provided, however, that so long as no Event of Default shall
      have occurred and be continuing, the Collateral Agent shall return such
      Instrument or Tangible Chattel Paper to such Issuer from time to time, to
      the extent necessary for collection in the ordinary course of such
      Issuer's business.

            (b) Deposit Accounts. Each Issuer hereby represents and warrants
      that (i) as of the date hereof, it has neither opened nor maintains any
      Deposit Accounts related to the Collateral other than the accounts listed
      in Schedule 17 of the Perfection Certificate, (ii) each Issuer, as
      applicable, will execute and deliver, as of the date hereof, a Control
      Agreement substantially in the form set forth in Exhibit 2(a) hereof (or
      in such other form and substance as is reasonably acceptable to the
      Collateral Agent) for the Deposit Accounts listed in Schedule 17 of the
      Perfection Certificate or close such account and (iii) as of the date each
      such Control Agreement shall be executed, the Collateral Agent will

                                      -22-
<PAGE>
      have a perfected first priority Security Interest in each Deposit Account
      listed in Schedule 17 of the Perfection Certificate by Control. No Issuer
      shall hereafter establish and maintain any Deposit Account related to the
      Collateral unless (1) such Issuer shall have given the Collateral Agent 30
      days' prior written notice of its intention to establish such new Deposit
      Account with a Bank, (2) such Bank shall be reasonably acceptable to the
      Collateral Agent and (3) such Bank and such Issuer shall have duly
      executed and delivered to the Collateral Agent a Control Agreement with
      respect to such Deposit Account. The Collateral Agent agrees with each
      Issuer that the Collateral Agent shall not give any instructions directing
      the disposition of funds from time to time credited to any Deposit Account
      related to the Collateral or withhold any withdrawal rights from each
      Issuer with respect to funds from time to time credited to any Deposit
      Account related to the Collateral unless an Event of Default has occurred
      and is continuing, or, after giving effect to any withdrawal that would
      occur. The provisions of this Section 3.4(b) shall not apply to such
      Deposit Accounts related to the Collateral for which the Collateral Agent
      is the Bank. No Issuer shall grant Control of any Deposit Account related
      to the Collateral to any Person other than the Collateral Agent.

            (c) Investment Property. Each Issuer hereby represents and warrants
      that (i) as of the date hereof it has neither opened nor maintains any
      Securities Accounts or Commodity Accounts other than those listed in
      Schedule 17 of the Perfection Certificate, (ii) it will, on the Date of
      Closing, execute and deliver a Control Agreement substantially in the form
      set forth in Exhibit 2(b) hereto (or such other form and substance
      acceptable to the Collateral Agent) for each Securities Account or
      Commodity Account listed on Schedule 17 of the Perfection Certificate or
      close such account, (iii) as of the date each such Control Agreement is
      executed the Collateral Agent will have a perfected first priority
      security interest in such Securities Accounts and Commodity Accounts by
      Control and (iv) it does not hold, own or have any interest in any
      certificated securities or uncertificated securities other than those
      constituting Pledged Securities and those maintained in Securities
      Accounts or Commodity Accounts listed in Schedule 17 of the Perfection
      Certificate.

            (i) If any Issuer shall at any time hold or acquire any certificated
      securities constituting Investment Property, such Issuer shall immediately
      endorse, assign and deliver the same to the Collateral Agent, accompanied
      by such instruments of transfer or assignment duly executed in blank, all
      in form and substance reasonably satisfactory to the Collateral Agent. If
      any securities now or hereafter acquired by any Issuer constituting
      Investment Property are uncertificated and are issued to such Issuer or
      its nominee directly by the issuer thereof, such Issuer shall immediately
      notify the Collateral Agent thereof and pursuant to an agreement in form
      and substance reasonably satisfactory to the Collateral Agent, either (a)
      cause the issuer to agree to comply with instructions from the Collateral
      Agent as to such securities, without further consent of such Issuer or
      such nominee, or (b) arrange for the Collateral Agent to become the
      registered owner of the securities. No Issuer shall hereafter establish
      and maintain any Securities Account or Commodity Account with any
      Securities Intermediary or Commodity Intermediary un-

                                      -23-
<PAGE>
      less (1) such Issuer shall have given the Collateral Agent 15 days' prior
      written notice of its intention to establish such new Securities Account
      or Commodity Account with such Securities Intermediary or Commodity
      Intermediary, (2) such Securities Intermediary or Commodity Intermediary
      shall be reasonably acceptable to the Collateral Agent and (3) such
      Securities Intermediary or Commodity Intermediary, as the case may be, and
      such Issuer shall have duly executed and delivered a Control Agreement
      with respect to such Securities Account or Commodity Account, as the case
      may be. Each Issuer shall accept any cash and Investment Property in trust
      for the benefit of the Collateral Agent and within one (1) Business Day of
      actual receipt thereof, deposit any cash or Investment Property and any
      new securities, instruments, documents or other property by reason of
      ownership of the Investment Property (other than payments of a kind
      described in Section 7.5 hereof) received by it into a Controlled Account.
      The Collateral Agent agrees with each Issuer that the Collateral Agent
      shall not give any instructions or directions to any issuer of
      uncertificated securities, Securities Intermediary or Commodity
      Intermediary, and shall not withhold its consent to the exercise of any
      withdrawal or dealing rights by such Issuer, unless an Event of Default
      has occurred and is continuing, or, after giving effect to any such
      investment and withdrawal rights would occur. Except for the provisions in
      the preceding sentence, the provisions of this Section 3.4(c) shall not
      apply to any Financial Assets credited to a Securities Account for which
      the Collateral Agent is the Securities Intermediary. No Issuer shall grant
      control over any Investment Property to any Person other than the
      Collateral Agent.

            (ii) As between the Collateral Agent and the Issuers, the Issuers
      shall bear the investment risk with respect to the Investment Property,
      and the risk of loss of, damage to, or the destruction of the Investment
      Property, whether in the possession of, or maintained as a security
      entitlement or deposit by, or subject to the control of, the Collateral
      Agent, a Securities Intermediary, Commodity Intermediary, any Issuer or
      any other Person; provided, however, that nothing contained in this
      Section 3.4(c) shall release or relieve any Securities Intermediary or
      Commodity Intermediary of its duties and obligations to any Issuer or any
      other Person under any Control Agreement or under applicable law. Each
      Issuer shall promptly pay all Charges and fees of whatever kind or nature
      with respect to the Investment Property pledged by it under this
      Agreement. In the event any Issuer shall fail to make such payment
      contemplated in the immediately preceding sentence, the Collateral Agent
      may, but shall not be required to, do so for the account of such Issuer
      and such Issuer shall promptly reimburse and indemnify the Collateral
      Agent from all costs and expenses incurred by the Collateral Agent under
      this Section 3.4(c) in accordance with Section 11.4 hereof.

            (d) Electronic Chattel Paper and Transferable Records. If any amount
      individually or in the aggregate in excess of $100,000 payable under or in
      connection with any of the Collateral shall be evidenced by any Electronic
      Chattel Paper or any "transferable record," as that term is defined in
      Section 201 of the Federal Electronic Signatures in Global and National
      Commerce Act, or in Section 16 of the Uniform Electronic Transactions Act
      as in effect in any relevant jurisdiction, upon acquiring such Electronic
      Chattel

                                      -24-
<PAGE>
      Paper or transferable record the Issuer acquiring such Electronic Chattel
      Paper or transferable record shall promptly notify the Collateral Agent
      thereof and shall take such action as the Collateral Agent may reasonably
      request to vest in the Collateral Agent control under UCC Section 9-105 of
      such Electronic Chattel Paper or control under Section 201 of the Federal
      Electronic Signatures in Global and National Commerce Act or, as the case
      may be, Section 16 of the Uniform Electronic Transactions Act, as so in
      effect in such jurisdiction, of such transferable record. The Collateral
      Agent agrees with each Issuer that the Collateral Agent will arrange,
      pursuant to procedures satisfactory to the Collateral Agent and so long as
      such procedures will not result in the Collateral Agent's loss of control,
      for the Issuer to make alterations to the Electronic Chattel Paper or
      transferable record permitted under UCC Section 9-105 or, as the case may
      be, Section 201 of the Federal Electronic Signatures in Global and
      National Commerce Act or Section 16 of the Uniform Electronic Transactions
      Act for a party in control to allow without loss of control, unless an
      Event of Default has occurred and is continuing or would occur after
      taking into account any action by such Issuer with respect to such
      Electronic Chattel Paper or transferable record.

            (e) Letter-of-Credit Rights. If any Issuer is at any time a
      beneficiary under a Letter of Credit now or hereafter issued in favor of
      such Issuer in an amount individually or in the aggregate in excess of
      $100,000, the Issuer shall promptly notify the Collateral Agent thereof
      and the Issuer shall, pursuant to an agreement in form and substance
      reasonably satisfactory to the Collateral Agent, either (i) arrange for
      the issuer and any confirmer of such Letter of Credit to consent to an
      assignment to the Collateral Agent of the proceeds of any drawing under
      the Letter of Credit or (ii) arrange for the Collateral Agent to become
      the transferee beneficiary of such Letter of Credit, with the Collateral
      Agent agreeing, in each case, that the proceeds of any drawing under the
      Letter of Credit are to be applied as provided in the Purchase Agreements.

            (f) Commercial Tort Claims. As of the date hereof each Issuer hereby
      represents and warrants that it holds no Commercial Tort Claims related to
      the Collateral other than those listed in Schedule 16 of the Perfection
      Certificate. If any Issuer shall at any time hold or acquire a Commercial
      Tort Claim related to the Collateral having a value individually or in the
      aggregate in excess of $100,000, such Issuer shall immediately notify the
      Collateral Agent in writing signed by the Issuer of the brief details
      thereof and grant to the Collateral Agent in such writing a security
      interest therein and in the Proceeds thereof, all upon the terms of this
      Agreement, with such writing to be in form and substance reasonably
      satisfactory to the Collateral Agent.

            (g) Bailee Letters. Each Issuer shall use its commercially
      reasonable efforts to obtain as soon as practicable after the date hereof
      with respect to each location listed in Schedule 2(d) annexed to the
      Perfection Certificate, where such Issuer maintains Collateral, a waiver
      of bailee's lien substantially in the form of Exhibit 3 annexed hereto
      (each a "Bailee Letter") and use commercially reasonable efforts to obtain
      a Bailee Letter from all such bailees who from time to time have
      possession of Collateral in the ordinary course of such Issuer's business.

                                      -25-
<PAGE>
            SECTION 3.5 Joinder of Additional Guarantors. The Issuers shall
cause each domestic Subsidiary of the Company to pledge its assets to the
Collateral Agent for the benefit of the Secured Parties, and to execute and
deliver to the Collateral Agent (i) an instrument in the form of Exhibit 5
hereto, and (ii) a Perfection Certificate, in each case, within 10 Business Days
of the date on which it was acquired or created and, upon such execution and
delivery, such Subsidiary shall constitute a "Guarantor" and an "Issuer" for all
purposes hereunder with the same force and effect as if originally named as a
Guarantor and Issuer herein. The execution and delivery of any such instrument
shall not require the consent of any Issuer hereunder. The rights and
obligations of each Issuer hereunder shall remain in full force and effect
notwithstanding the addition of any new Guarantor and Issuer as a party to this
Agreement.

            SECTION 3.6 Use and Pledge of Collateral. Unless an Event of Default
shall have occurred and be continuing, the Collateral Agent shall from time to
time execute and deliver, upon written request of any Issuer and at the sole
cost and expense of such Issuer, any and all instruments, certificates or other
documents, in a form reasonably requested by such Issuer, necessary or
appropriate in the reasonable judgment of such Issuer to enable any Issuer to
continue to exploit, license, use, enjoy and protect the Collateral in
accordance with the terms hereof and of the Purchase Agreements. The Issuers and
the Collateral Agent acknowledge that this Agreement is intended to grant to the
Collateral Agent for the benefit of the Secured Parties security interests in
and Liens upon the Collateral and shall not constitute or create a present
assignment of any of the Collateral.

                                   ARTICLE IV

                    REPRESENTATIONS, WARRANTIES AND COVENANTS

            Each Issuer represents, warrants and covenants as follows:

            SECTION 4.1 Title, Authority and Validity; Preservation of Corporate
Existence(i) . (i) Each Issuer (A) has good and valid rights in and title to the
Collateral with respect to which it has purported to grant security interests
and Liens hereunder, (B) has full power and authority to grant to the Collateral
Agent the security interests in and Liens on such Collateral pursuant hereto and
to execute, deliver and perform its obligations in accordance with the terms of
this Agreement, without the consent or approval of any other Person other than
any consent or approval that has been obtained, (C) is duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
organization, (D) it is duly qualified to transact business and is in good
standing in each state in which the Collateral is located and (E) this Agreement
is a legal, valid and binding obligation of such Issuer, enforceable against
such Issuer in accordance with its terms.

            (ii) Each Issuer shall (A) preserve and maintain in full force and
effect its existence and good standing under the laws of the jurisdiction of its
organization, (B) preserve and maintain in full force and effect its
qualification to transact business and good standing in the

                                      -26-
<PAGE>
state in which the Collateral is located and (C) preserve and maintain in full
force and effect all consents, authorizations and approvals necessary or
required of any Governmental Authority or any other Person relating to the
execution, delivery and performance hereof.

            SECTION 4.2 Validity of Security Interests. The security interests
in and Liens on the Collateral granted to the Collateral Agent for the benefit
of the Secured Parties hereunder constitutes (a) legal and valid security
interests in all the Collateral securing the payment and performance of the
Secured Obligations, and (b) subject to the filings described in Schedule 7 of
the Perfection Certificate, perfected security interests in all the Collateral.
Subject to Section 2.3 of this Agreement, the security interests and Liens
granted to the Collateral Agent for the benefit of the Secured Parties pursuant
to this Agreement in and on the Collateral will at all times constitute
perfected, continuing first and second priority security interests therein,
superior and prior to the rights of all other Persons therein other than in the
case of any Collateral with respect to the holders of Permitted Collateral
Liens.

            SECTION 4.3 Limitation on Liens. Each Issuer is as of the date
hereof, and, as to Collateral acquired by it from time to time after the date
hereof, each Issuer will be, the sole direct and beneficial owner or licensee of
all Collateral pledged by it hereunder free from any Lien or other right, title
or interest of any Person other than (i) Prior Liens, (ii) the Lien and security
interests created by this Agreement, (iii) Contested Liens and (iv) the Liens
described in Paragraph 6F of the Securities Purchase Agreement (the Liens
described in clauses (i) through (iv) of this sentence, collectively, "Permitted
Collateral Liens"). Each Issuer shall, at its own cost and expense, defend title
to the Collateral pledged by it hereunder and the security interests therein and
Liens thereon granted to the Collateral Agent and the priority thereof against
all claims and demands of all Persons, at its own cost and expense, at any time
claiming any interest therein adverse to the Collateral Agent or any other
Secured Party. There is no agreement, and no Issuer shall enter into any
agreement or take any other action, that would result in the imposition of any
other Lien, restrict the transferability of any of the Collateral or otherwise
impair or conflict with such Issuer's obligations or the rights of the
Collateral Agent hereunder; provided, that if the obligations under the
Securities shall no longer be outstanding (whether by maturity, redemption or
otherwise), each Issuer may, upon notice to the Collateral Agent, grant a Lien
in the Collateral to a third-party that is subordinated to the Liens granted
under this Agreement ("Subordinated Liens").

            SECTION 4.4 Other Financing Statements. There is no (nor will there
be any) valid or effective financing statement (or similar statement or
instrument of registration under the law of any jurisdiction) covering or
purporting to cover any interest of any kind in the Collateral other than in the
case of Collateral financing statements relating to Permitted Collateral Liens.
So long as any of the Secured Obligations remain unpaid, no Issuer shall
execute, authorize or permit to be filed in any public office any financing
statement (or similar statement or instrument of registration under the law of
any jurisdiction) or statements relating to any Collateral, except, in the case
of any Collateral, financing statements filed or to be filed in respect of and
covering the security interests granted by such Issuer to the holders of the
Permitted Collateral Liens and Subordinated Liens.

                                      -27-
<PAGE>
            SECTION 4.5 Chief Executive Office; Change of Name; Jurisdiction of
Organization. (a) The exact legal name, type of organization, jurisdiction of
organization, Federal Taxpayer Identification Number, organizational
identification number and chief executive office of each Issuer is indicated
next to its name in Schedules 1(a) and 2(a) of the Perfection Certificate. No
Issuer shall change (i) its corporate name, (ii) the location of its chief
executive office, its principal place of business, any office in which it
maintains books or records relating to Collateral owned by it or any office or
facility at which Collateral owned by it is located (including the establishment
of any such new office or facility), (iii) its identity or type of organization
or corporate structure, (iv) its Federal Taxpayer Identification Number or
organizational identification number or (v) its jurisdiction of organization (in
each case, including, without limitation, by merging with or into any other
entity, reorganizing, dissolving, liquidating, reincorporating or incorporating
in any other jurisdiction) until (A) it shall have given the Collateral Agent
not less than 30 days' prior written notice (in the form of an Officers'
Certificate) of its intention so to do, clearly describing such change and
providing such other information in connection therewith as the Collateral Agent
may reasonably request and (B) with respect to such change, such Issuer shall
have taken all action reasonably satisfactory to the Collateral Agent to
maintain the perfection and priority of the security interests of the Collateral
Agent for the benefit of the Secured Parties in the Collateral intended to be
granted hereunder, including, without limitation, using commercially reasonable
efforts to obtain waivers of landlord's or warehousemen's liens with respect to
such new location, if applicable. Each Issuer agrees to promptly provide the
Collateral Agent with certified organizational documents reflecting any of the
changes described in the preceding sentence.

            (b) The Collateral Agent may rely on opinions of counsel as to
whether any or all UCC financing statements of each Issuer need to be amended as
a result of any of the changes described in Section 4.5(a). If any Issuer fails
to provide information to the Collateral Agent about such changes on a timely
basis, the Collateral Agent shall not be liable or responsible to any party for
any failure to maintain perfected security interests in such Issuer's property
constituting Collateral, for which the Collateral Agent needed to have
information relating to such changes. The Collateral Agent shall have no duty to
inquire about such changes if any Issuer does not inform the Collateral Agent of
such changes, the parties acknowledging and agreeing that it would not be
feasible or practical for the Collateral Agent to search for information on such
changes if such information is not provided by any Issuer.

            SECTION 4.6 Location of Inventory and Equipment. All Equipment and
Inventory constituting Collateral of each Issuer is located at the chief
executive office or such other location listed in Schedules 2(a), 2(b), 2(c),
2(d) or 2(e) of the Perfection Certificate. No Issuer shall move any Equipment
or Inventory exclusively related to the Collateral to any location other than
one within the Continental United States that is listed in such Schedules of the
Perfection Certificate with respect to such Issuer until (i) it shall have given
the Collateral Agent not less than 30 days' prior written notice (in the form of
an Officers' Certificate) of its intention so to do, clearly describing such new
location within the Continental United States and providing such other
information in connection therewith as the Collateral Agent may request and (ii)
with respect to such new location, each Issuer shall have taken all action
reasonably satisfactory to the

                                      -28-
<PAGE>
Collateral Agent to maintain the perfection and priority of the security
interests of the Collateral Agent for the benefit of the Secured Parties in the
Collateral intended to be granted hereby, including, without limitation, using
commercially reasonable efforts to obtain waivers of landlord's or
warehouseman's liens with respect to such new location, if applicable.

            SECTION 4.7 Condition and Maintenance of Equipment. The Equipment
constituting Collateral of each Issuer is in good repair, working order and
condition, reasonable wear and tear excepted. Each Issuer shall cause any
Equipment acquired exclusively in connection with the Collateral to be
maintained and preserved in good repair, working order and condition, reasonable
wear and tear excepted, and shall as quickly as commercially practicable make or
cause to be made all repairs, replacements and other improvements which are
necessary or appropriate in the conduct of such Issuer's business.

            SECTION 4.8 Corporate Names; Prior Transactions. No Issuer has,
during the past five years, been known by or used any other corporate or
fictitious name or been a party to any merger or consolidation, or acquired all
or substantially all of the assets of any Person, or acquired any of its
property or assets out of the ordinary course of business, except as set forth
in Schedules 1(b), 1(c) and 4 of the Perfection Certificate.

            SECTION 4.9 No Claims. Each Issuer owns or has rights to use all of
the Collateral pledged by it hereunder and all rights with respect to any of the
foregoing used in, necessary for or material to such Issuer's business as
currently conducted. The use by such Issuer of such Collateral and all such
rights with respect to the foregoing do not infringe on the rights of any Person
other than such infringement which would not, individually or in the aggregate,
result in a Collateral Material Adverse Effect. No claim has been made and
remains outstanding that any Issuer's use of any Collateral does or may violate
the rights of any third Person that would individually, or in the aggregate,
have a Collateral Material Adverse Effect.

            SECTION 4.10 No Conflicts, Consents, etc. Neither the execution and
delivery hereof by each Issuer nor the consummation of the transactions herein
contemplated nor the fulfillment of the terms hereof (i) violates any Operative
Agreement of any Issuer, (ii) violates the terms of any agreement, indenture,
mortgage, deed of trust, equipment lease, instrument or other document to which
any Issuer is a party, or by which it may be bound or to which any of its
properties or assets may be subject, which violation would, individually or in
the aggregate, have a Collateral Material Adverse Effect, (iii) conflicts with
any Requirement of Law applicable to any Issuer or its property, which conflict
would, individually or in the aggregate, have a Collateral Material Adverse
Effect, or (iv) results in or requires the creation or imposition of any Lien
(other than the Liens contemplated hereby) upon or with respect to any of the
property now owned or hereafter acquired by any Issuer. No consent of any party
(including, without limitation, equityholders or creditors of any Issuer) and no
consent, authorization, approval, license or other action by, and no notice to
or filing with, any Governmental Authority or regulatory body or other Person is
required (A) for the pledge by each Issuer of the Collateral pledged by it
pursuant to this Agreement or for the execution, delivery or performance hereof
by each Issuer, except as set forth in Schedule 4.10 attached hereto, (B) for
the exercise by the Collateral Agent of the rights provided for in this
Agreement or (C) for the exercise by the Collateral Agent of the

                                      -29-
<PAGE>
remedies in respect of the Collateral pursuant to this Agreement. In the event
that the Collateral Agent desires to exercise any remedies, rights and powers
set forth in this Agreement and determines it necessary to obtain any approvals
or consents of any Governmental Authority or any other Person therefor, then,
upon the reasonable request of the Collateral Agent, each Issuer agrees to use
its best efforts to assist and aid the Collateral Agent to obtain as soon as
practicable any necessary approvals or consents for the exercise of any such
remedies, rights and powers.

            SECTION 4.11 Collateral. All information set forth herein, including
the schedules attached hereto, and all information contained in any documents,
schedules and lists heretofore delivered to any Secured Party in connection with
this Agreement, in each case, relating to the Collateral, is accurate and
complete in all material respects. The Collateral described on the schedules
attached hereto constitutes all of the property of such type of Collateral owned
or held by any Issuer.

            SECTION 4.12 Insurance. (a) Each Issuer, at its own expense, shall
maintain or cause to be maintained the insurance policies and coverages required
under Paragraph 5H of the Securities Purchase Agreement with respect to the
Collateral.

            (b) If there shall occur any Destruction, individually or in the
aggregate, in excess of $100,000, each Issuer shall promptly send to the
Collateral Agent a written notice setting forth the nature and extent of such
Destruction. If there shall occur any Taking, the applicable Issuer shall
immediately notify the Collateral Agent upon receiving notice of such Taking or
commencement of proceedings therefor. The Net Insurance Proceeds are hereby
assigned and shall be paid to the Collateral Agent. Each Issuer shall take all
steps necessary to notify the condemning authority of such assignment. All Net
Insurance Proceeds shall be applied in accordance with the provisions of
Paragraph 5H of the Securities Purchase Agreement.

            (c) In the event that the proceeds of any insurance claim are paid
after the Collateral Agent has exercised its right to foreclose after an Event
of Default such proceeds shall be paid to the Collateral Agent to satisfy any
deficiency remaining after such foreclosure. The Collateral Agent shall retain
its interest in the Insurance Policies required to be maintained pursuant to
this Agreement during any redemption period.

            SECTION 4.13 Payment of Taxes; Compliance with Laws; Contesting
Liens; Claims. Each Issuer represents and warrants that all Charges imposed upon
or assessed against the Collateral have been paid and discharged except to the
extent such Charges constitute a Lien not yet due and payable or a Permitted
Collateral Lien. Each Issuer shall comply with all Requirements of Law
applicable to the Collateral the failure to comply with which would,
individually or in the aggregate, have a Collateral Material Adverse Effect. Any
Issuer may at its own expense contest the validity, amount or applicability of
any Charges so long as the contest thereof shall be conducted in accordance
with, and permitted pursuant to the provisions of, the Purchase Agreements.
Notwithstanding the foregoing provisions of this Section 4.13, (i) no contest of
any such obligation may be pursued by any Issuer if such contest would expose
the Collateral Agent or any other Secured Party to (A) any possible criminal
liability or (B) any additional civil liability for failure to comply with such
obligations unless such Issuer shall have fur-

                                      -30-
<PAGE>
nished a bond or other security therefor satisfactory to the Collateral
Agent, or such Secured Party, as the case may be, and (ii) if at any time
payment or performance of any obligation contested by such Issuer pursuant to
this Section 4.13 shall become necessary to prevent the imposition of remedies
because of non-payment, such Issuer shall pay or perform the same, in sufficient
time to prevent the imposition of remedies in respect of such default or
prospective default.

            SECTION 4.14 Access to Collateral, Books and Records; Other
Information. Upon reasonable request and prior notice to the Issuers, the
Collateral Agent, its agents, accountants and attorneys shall have full and free
access to visit and inspect, as applicable, during normal business hours and
such other reasonable times as may be requested by the Collateral Agent all of
the Collateral including, without limitation, all of the books, correspondence
and records of any Issuer relating thereto. The Collateral Agent and its
representatives may examine the same, take extracts therefrom and make
photocopies thereof, and each Issuer agrees to render to the Collateral Agent at
such Issuer's cost and expense, such clerical and other assistance as may be
reasonably requested by the Collateral Agent with regard thereto. Each Issuer
shall, at any and all times, within a reasonable time after written request by
the Collateral Agent, furnish or cause to be furnished to the Collateral Agent,
in such manner and in such detail as may be reasonably requested by the
Collateral Agent, additional information with respect to the Collateral.

                                   ARTICLE V

              CERTAIN PROVISIONS CONCERNING SECURITIES COLLATERAL

            SECTION 5.1 Pledge of Additional Securities Collateral. Each Issuer
shall, upon obtaining any Pledged Securities or Intercompany Notes of any
person, accept the same in trust for the benefit of the Collateral Agent and
forthwith deliver to the Collateral Agent a pledge amendment, duly executed by
such Issuer, in substantially the form of Exhibit 4 annexed hereto (each, a
"Pledge Amendment"), and the certificates and other documents required under
Section 3.1 and Section 3.2 in respect of the additional Pledged Securities or
Intercompany Notes which are to be pledged pursuant to this Agreement, and
confirming the attachment of the Lien hereby created on and in respect of such
additional Pledged Securities or Intercompany Notes. Each Issuer hereby
authorizes the Collateral Agent to attach each Pledge Amendment to this
Agreement and agrees that all Pledged Interests or Intercompany Notes listed on
any Pledge Amendment delivered to the Collateral Agent shall for all purposes
hereunder be considered Collateral.

            SECTION 5.2 Voting Rights; Distributions; etc(i) . (i) So long as no
Event of Default shall have occurred and be continuing:

            (A) Each Issuer shall be entitled to exercise any and all voting and
      other consensual rights pertaining to the Securities Collateral or any
      part thereof for any purpose not inconsistent with the terms or purposes
      hereof or any other document evidencing the Obligations; provided,
      however, that no Issuer shall in any event exercise such rights in any
      manner which may have a Collateral Material Adverse Effect.

                                      -31-
<PAGE>
            (B) Each Issuer shall be entitled to receive and retain, and to
      utilize free and clear of the Lien hereof, any and all Distributions;
      provided, however, that any and all such Distributions consisting of
      rights or interests in the form of securities shall be forthwith delivered
      to the Collateral Agent to hold as Collateral and shall, if received by
      such Issuer, be received in trust for the benefit of the Collateral Agent,
      be segregated from the other property or funds of such Issuer and be
      forthwith delivered to the Collateral Agent as Collateral in the same form
      as so received (with any necessary endorsement).

            (C) The Collateral Agent shall be deemed without further action or
      formality to have granted to each Issuer all necessary consents relating
      to voting rights and shall, if necessary, upon written request of any
      Issuer and at the sole cost and expense of such Issuer, from time to time
      execute and deliver (or cause to be executed and delivered) to such Issuer
      all such instruments as such Issuer may reasonably request in order to
      permit such Issuer to exercise the voting and other rights which it is
      entitled to exercise pursuant to Section 5.2(i)(A) hereof and to receive
      the Distributions which it is authorized to receive and retain pursuant to
      Section 5.2(i)(B) hereof.

            (ii) Upon the occurrence and during the continuance of any Event of
Default:

            (A) All rights of each Issuer to exercise the voting and other
      consensual rights it would otherwise be entitled to exercise pursuant to
      Section 5.2(i)(A) hereof without any further action shall cease, and all
      such rights shall thereupon become vested in the Collateral Agent, which
      shall thereupon have the sole right to exercise such voting and other
      consensual rights.

            (B) All rights of each Issuer to receive Distributions which it
      would otherwise be authorized to receive and retain pursuant to Section
      5.2(i)(B) hereof shall cease and all such rights shall thereupon become
      vested in the Collateral Agent, which shall thereupon have the sole right
      to receive and hold as Collateral such Distributions.

            (iii) Each Issuer shall, at its sole cost and expense, from time to
time execute and deliver to the Collateral Agent appropriate instruments as the
Collateral Agent may request in order to permit the Collateral Agent to exercise
the voting and other rights which it may be entitled to exercise pursuant to
Section 5.2(ii)(A) hereof and to receive all Distributions which it may be
entitled to receive under Section 5.2(ii)(B) hereof.

            (iv) All Distributions which are received by any Issuer contrary to
the provisions of Section 5.2(ii)(B) hereof shall be received in trust for the
benefit of the Collateral Agent, shall be segregated from other funds of such
Issuer and shall immediately be paid over to the Collateral Agent as Collateral
in the same form as so received (with any necessary endorsement).

            SECTION 5.3 Operative Agreements. Each Issuer has delivered to the
Collateral Agrent true, correct and complete copies of its Operative Agreements.
The Operative Agreements are in full force and effect, have not as of the date
hereof been amended or modified except as disclosed to the Collateral Agent, and
there is no existing default by any party thereun-

                                      -32-
<PAGE>
der or any event which, with the giving of notice of passage of time or both,
would constitute a default by any party thereunder. Each Issuer shall deliver to
the Collateral Agent a copy of any notice of default given or received by it
under any Operative Agreement within ten days after such Issuer gives or
receives such notice. No Issuer will terminate or agree to terminate any
Operative Agreement or make any amendment or modification to any Operative
Agreement which may have a Collateral Material Adverse Effect including electing
to treat any Pledged Interests of such Issuer as a security under Section 8-103
of the UCC.

            SECTION 5.4 Defaults, etc. No Issuer is in default in the payment of
any portion of any mandatory capital contribution, if any, required to be made
under any agreement to which such Issuer is a party relating to the Pledged
Securities pledged by it, and no Issuer is in violation of any other provisions
of any such agreement to which such Issuer is a party, or otherwise in default
or violation thereunder. No Securities Collateral pledged by any Issuer is
subject to any defense, offset or counterclaim, nor have any of the foregoing
been asserted or alleged against any Issuer by any Person with respect thereto,
and as of the date hereof, there are no certificates, instruments, documents or
other writings (other than the Operative Agreements and certificates, if any,
delivered to the Collateral Agent) which evidence any Pledged Securities of any
Issuer.

                                   ARTICLE VI

                   CERTAIN PROVISIONS CONCERNING INTELLECTUAL
                               PROPERTY COLLATERAL

            SECTION 6.1 Grant of License. For the purpose of enabling the
Collateral Agent, during the continuance of an Event of Default, to exercise
rights and remedies under Article IX hereof at such time as the Collateral Agent
shall be lawfully entitled to exercise such rights and remedies, and for no
other purpose, each Issuer hereby grants to the Collateral Agent, to the extent
assignable, an irrevocable, non-exclusive license (exercisable without payment
of royalty or other compensation to such Issuer) to use, assign, license or
sublicense any of the Intellectual Property Collateral now owned or hereafter
acquired by such Issuer, wherever the same may be located, including in such
license access to all media in which any of the licensed items may be recorded
or stored and to all computer programs used for the compilation or printout
hereof.

            SECTION 6.2 Registrations. Except pursuant to licenses and other
user agreements entered into by any Issuer in the ordinary course of business
that are listed in Schedules 15(a) and (b) annexed to the Perfection
Certificate, on and as of the date hereof (i) each Issuer owns and possesses the
right to use, and has done nothing to authorize or enable any other Person to
use, any Copyright, Patent or Trademark listed in Schedules 15(a) and (b)
annexed to the Perfection Certificate, and (ii) to any Issuer's knowledge, all
registrations listed in Schedules 15(a) and (b) annexed to the Perfection
Certificate are valid and in full force and effect.

                                      -33-
<PAGE>
            SECTION 6.3 No Violations or Proceedings. To any Issuer's knowledge,
on and as of the date hereof, (i) except as set forth in Schedule 6.3 attached
hereto, there is no material violation by others of any right of such Issuer
with respect to any Copyright, Patent or Trademark listed in Schedules 15(a) and
(b) annexed to the Perfection Certificate, respectively, pledged by it under the
name of such Issuer, (ii) no Issuer is infringing upon any Copyright, Patent or
Trademark of any other Person other than such infringement that, individually or
in the aggregate, would not (or would not reasonably be expected to) result in a
material adverse effect on the value or utility of the Intellectual Property
Collateral or any portion thereof material to the use and operation of the
Collateral and (iii) no proceedings have been instituted or are pending against
any Issuer or, to any Issuer, knowledge, threatened, and no claim against any
Issuer has been received by such Issuer, alleging any such violation, except as
may be set forth in Schedule 6.3.

            SECTION 6.4 Protection of Collateral Agent's Security. On a
continuing basis, each Issuer shall, at its sole cost and expense, (i) promptly
following its becoming aware thereof, notify the Collateral Agent of (A) any
materially adverse determination in any proceeding in the United States Patent
and Trademark Office or the United States Copyright Office with respect to any
material Patent, Trademark or Copyright in relation to the Collateral or (B) the
institution of any proceeding or any adverse determination in any Federal, state
or local court or administrative body regarding such Issuer's claim of ownership
in or right to use any of the Intellectual Property Collateral material to the
use and operation of the Collateral, its right to register such Intellectual
Property Collateral or its right to keep and maintain such registration in full
force and effect, (ii) to the extent permitted under the Acquisition Documents
as in effect on the date hereof maintain and protect the Intellectual Property
Collateral material to the use and operation of the Collateral as presently used
and operated and as contemplated by the Purchase Agreements, (iii) to the extent
permitted under the Acquisition Documents as in effect on the date hereof not
permit to lapse or become abandoned any Intellectual Property Collateral
material to the use and operation of the Collateral as presently used and
operated and as contemplated by the Purchase Agreements, and not settle or
compromise any pending or future litigation or administrative proceeding with
respect to such Intellectual Property Collateral, in each case except as shall
be consistent with commercially reasonable business judgment, (iv) upon such
Issuer obtaining knowledge thereof, promptly notify the Collateral Agent in
writing of any event which may be reasonably expected to materially and
adversely affect the value or utility of the Intellectual Property Collateral or
any portion thereof material to the use and operation of the Collateral, the
ability of such Issuer or the Collateral Agent to dispose of the Intellectual
Property Collateral or any portion thereof or the rights and remedies of the
Collateral Agent in relation thereto including, without limitation, a levy or
threat of levy or any legal process against the Intellectual Property Collateral
or any portion thereof, (v) not license the Intellectual Property Collateral
other than licenses entered into by such Issuer in, or incidental to, the
ordinary course of business, or amend or permit the amendment of any of the
licenses in a manner that materially and adversely affects the right to receive
payments thereunder, or in any manner that would materially impair the value of
the Intellectual Property Collateral or the Liens on and security interests in
the Intellectual Property Collateral intended to be granted to the Collateral
Agent for the benefit of the Secured Parties, without the consent of the
Collateral Agent, (vi) until the Collat-

                                      -34-
<PAGE>
eral Agent exercises its rights to make collection, diligently keep adequate
records respecting the Intellectual Property Collateral and (vii) furnish to the
Collateral Agent from time to time upon the Collateral Agent's reasonable
request therefor detailed statements and amended schedules further identifying
and describing the Intellectual Property Collateral and such other materials
evidencing or reports pertaining to the Intellectual Property Collateral as the
Collateral Agent may from time to time request.

            SECTION 6.5 After-Acquired Property. If any Issuer shall, at any
time before the Secured Obligations have been paid in full (other than
contingent indemnification obligations which, pursuant to the provisions of the
Purchase Agreements or the collateral documents, survive the termination
thereof), (i) obtain any rights to any additional Intellectual Property
Collateral or (ii) become entitled to the benefit of any additional Intellectual
Property Collateral or any renewal or extension thereof, including any reissue,
division, continuation, or continuation-in-part of any Intellectual Property
Collateral, or any improvement on any Intellectual Property Collateral, the
provisions hereof shall automatically apply thereto and any such item enumerated
in clause (i) or (ii) of this Section 6.5 with respect to the Issuers shall
automatically constitute Intellectual Property Collateral if such would have
constituted Intellectual Property Collateral at the time of execution hereof and
be subject to the Liens and security interests created by this Agreement without
further action by any party. Each Issuer shall promptly (x) provide to the
Collateral Agent written notice of any of the foregoing and (y) confirm the
attachment of the Liens and security interests created by this Agreement to any
rights described in clauses (x) and (y) of the immediately preceding sentence of
this Section 6.5 by execution of an instrument in form reasonably acceptable to
the Collateral Agent.

            SECTION 6.6 Modifications. Each Issuer authorizes the Collateral
Agent to modify this Agreement by amending Schedules 15(a) and (b) annexed to
the Perfection Certificate to include any Intellectual Property Collateral
acquired or arising after the date hereof of such Issuer including, without
limitation, any of the items listed in Section 6.5 hereof.

            SECTION 6.7 Litigation. Unless there shall occur and be continuing
any Event of Default, each Issuer shall have the right to commence and prosecute
in its own name, as the party in interest, for its own benefit and at the sole
cost and expense of such Issuer, such applications for protection of the
Intellectual Property Collateral and suits, proceedings or other actions to
prevent the infringement, counterfeiting, unfair competition, dilution,
diminution in value or other damage as are necessary to protect the Intellectual
Property Collateral. Upon the occurrence and during the continuance of any Event
of Default, the Collateral Agent shall have the right but shall in no way be
obligated to file applications for protection of the Intellectual Property
Collateral and/or bring suit in the name of each Issuer, the Collateral Agent or
the Secured Parties to enforce the Intellectual Property Collateral and any
license thereunder. In the event of such suit, each Issuer shall, at the
reasonable request of the Collateral Agent, do any and all lawful acts and
execute any and all documents requested by the Collateral Agent in aid of such
enforcement and such Issuer shall promptly reimburse and indemnify the
Collateral Agent, as the case may be, for all costs and expenses incurred by the
Collateral Agent in the exercise of its rights under this Section 6.7 in
accordance with Section 11.3 hereof. In the event that the Collateral Agent
shall elect not to bring suit to enforce the Intellectual Property Collateral,
each Is-

                                      -35-
<PAGE>
suer agrees, at the reasonable request of the Collateral Agent, to take all
commercially reasonable actions necessary, whether by suit, proceeding or other
action, to prevent the infringement, counterfeiting, unfair competition,
dilution, diminution in value of or other damage to any of the Intellectual
Property Collateral by others and for that purpose agrees to diligently maintain
any suit, proceeding or other action against any Person so infringing necessary
to prevent such infringement.

                                   ARTICLE VII

                     CERTAIN PROVISIONS CONCERNING ACCOUNTS

            SECTION 7.1 Special Representations and Warranties. As of the time
when each of its Accounts in relation to the Collateral arises, each Issuer
shall be deemed to have represented and warranted that such Account and all
records, papers and documents relating thereto (i) are genuine and correct and
in all material respects what they purport to be, (ii) represent the legal,
valid and binding obligation of the account debtor, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws relating to or limiting creditors' rights generally
or by equitable principles relating to enforceability, evidencing indebtedness
unpaid and owed by such account debtor, arising out of the performance of labor
or services or the sale, lease, license, assignment or other disposition and
delivery of the goods or other property listed therein or out of an advance or a
loan, (iii) will, in the case of an Account relating to the Collateral, except
for the original or duplicate original invoice sent to a purchaser evidencing
such purchaser's account, be the only original writings evidencing and embodying
such obligation of the account debtor named therein and (iv) are in all material
respects in compliance and conform with all applicable Federal, state and local
laws and applicable laws of any relevant foreign jurisdiction.

            SECTION 7.2 Maintenance of Records. Each Issuer shall keep and
maintain at its own cost and expense complete records of each Account in
relation to the Collateral, in a manner consistent with prudent business
practice, including, without limitation, records of all payments received, all
credits granted thereon, all merchandise returned and all other documentation
relating thereto. Each Issuer shall, at such Issuer's sole cost and expense,
upon the Collateral Agent's demand made at any time after the occurrence and
during the continuance of any Event of Default, deliver all tangible evidence of
Accounts related to the Collateral, including, without limitation, all documents
evidencing Accounts related to the Collateral and any books and records relating
thereto to the Collateral Agent or to its representatives (copies of which
evidence and books and records may be retained by such Issuer). Upon the
occurrence and during the continuance of any Event of Default, the Collateral
Agent may transfer a full and complete copy of any Issuer's books, records,
credit information, reports, memoranda and all other writings relating to the
Accounts related to the Collateral to and for the use by any Person that has
acquired or is contemplating acquisition of an interest in the Accounts related
to the Collateral or the Collateral Agent's security interests therein without
the consent of any Issuer.

                                      -36-
<PAGE>
            SECTION 7.3 Legend. Each Issuer shall legend, at the request of the
Collateral Agent made at any time after the occurrence of any Event of Default
and in form and manner satisfactory to the Collateral Agent, the Accounts
related to the Collateral and the other books, records and documents of such
Issuer evidencing or pertaining to the Accounts related to the Collateral with
an appropriate reference to the fact that the Accounts related to the Collateral
have been assigned to the Collateral Agent for the benefit of the Secured
Parties and that the Collateral Agent has security interests therein.

            SECTION 7.4 Modification of Terms, etc. No Issuer shall rescind or
cancel any indebtedness evidenced by any Account related to the Collateral or
modify any term thereof or make any adjustment with respect thereto except in
the ordinary course of business consistent with prudent business practice, or
extend or renew any such indebtedness except in the ordinary course of business
consistent with prudent business practice or compromise or settle any dispute,
claim, suit or legal proceeding relating thereto or sell any Account related to
the Collateral or interest therein except in the ordinary course of business
consistent with prudent business practice without the prior written consent of
the Collateral Agent. Each Issuer shall timely fulfill all obligations on its
part to be fulfilled under or in connection with the Accounts related to the
Collateral.

            SECTION 7.5 Collection. Each Issuer shall cause to be collected from
the account debtor of each of the Accounts related to the Collateral, as and
when due in the ordinary course of business consistent with prudent business
practice (including, without limitation, Accounts related to the Collateral that
are delinquent, such Accounts to be collected in accordance with generally
accepted commercial collection procedures), any and all amounts owing under or
on account of such Account, and apply forthwith upon receipt thereof all such
amounts as are so collected to the outstanding balance of such Account, except
that any Issuer may, with respect to an Account related to the Collateral, allow
in the ordinary course of business (i) a refund or credit due as a result of
returned or damaged or defective merchandise and (ii) such extensions of time to
pay amounts due in respect of Accounts related to the Collateral and such other
modifications of payment terms or settlements in respect of Accounts related to
the Collateral as shall be commercially reasonable in the circumstances, all in
accordance with such Issuer's ordinary course of business consistent with its
collection practices as in effect from time to time. The costs and expenses
(including, without limitation, reasonable attorneys' fees) of collection, in
any case, whether incurred by any Issuer, the Collateral Agent or any Secured
Party, shall be paid by the Issuers.

                                  ARTICLE VIII

                            TRANSFERS AND OTHER LIENS

            SECTION 8.1 Transfers of and other Liens on Collateral. No Issuer
shall (i) sell, convey, assign or otherwise dispose of, or grant any option with
respect to, any of the Collateral pledged by it hereunder except as permitted by
the Purchase Agreements or (ii) create or

                                      -37-
<PAGE>
permit to exist any Lien upon or with respect to any of the Collateral pledged
by it hereunder other than in the case of Collateral, Permitted Collateral Liens
and Subordinated Liens.

                                   ARTICLE IX

                                    REMEDIES

            SECTION 9.1 Remedies. (a) Upon the occurrence and during the
continuance of any Event of Default the Collateral Agent may from time to time
exercise in respect of the Collateral, in addition to the other rights and
remedies provided for herein or otherwise available to it:

            (i) Personally, or by agents or attorneys, immediately take
      possession of the Collateral or any part thereof, from any Issuer or any
      other Person who then has possession of any part thereof with or without
      notice or process of law, and for that purpose may enter upon any Issuer's
      premises where any of the Collateral is located, remove such Collateral,
      remain present at such premises to receive copies of all communications
      and remittances relating to the Collateral and use in connection with such
      removal and possession any and all services, supplies, aids and other
      facilities of such Issuer;

            (ii) Demand, sue for, collect or receive any money or property at
      any time payable or receivable in respect of the Collateral including,
      without limitation, instructing the obligor or obligors on any agreement,
      instrument or other obligation constituting part of the Collateral to make
      any payment required by the terms of such agreement, instrument or other
      obligation directly to the Collateral Agent, and in connection with any of
      the foregoing, compromise, settle, extend the time for payment and make
      other modifications with respect thereto; provided, however, that in the
      event that any such payments are made directly to any Issuer, prior to
      receipt by any such obligor of such instruction, each Issuer shall
      segregate all amounts received pursuant thereto in trust for the benefit
      of the Collateral Agent and shall promptly (but in no event later than two
      Business Days after receipt thereof) pay such amounts to the Collateral
      Agent;

            (iii) Sell, assign, grant a license to use or otherwise liquidate,
      or direct any Issuer to sell, assign, grant a license to use or otherwise
      liquidate, any and all investments made in whole or in part with the
      Collateral or any part thereof, and take possession of the proceeds of any
      such sale, assignment, license or liquidation;

            (iv) Take possession of the Collateral or any part thereof, by
      directing any Issuer in writing to deliver the same to the Collateral
      Agent at any place or places so designated by the Collateral Agent, in
      which event such Issuer shall at its own expense: (A) forthwith cause the
      same to be moved to the place or places designated by the Collateral Agent
      and there delivered to the Collateral Agent, (B) store and keep any
      Collateral so delivered to the Collateral Agent at such place or places
      pending further action by the

                                      -38-
<PAGE>
      Collateral Agent and (C) while the Collateral shall be so stored and kept,
      provide such security and maintenance services as shall be necessary to
      protect the same and to preserve and maintain them in good condition. Each
      Issuer's obligation to deliver the Collateral as contemplated in this
      Section 9.1(iv) is of the essence hereof. Upon application to a court of
      equity having jurisdiction, the Collateral Agent shall be entitled to a
      decree requiring specific performance by each Issuer of such obligation;

            (v) Withdraw all moneys, instruments, securities and other property
      in any bank, financial securities, deposit or other account of any Issuer
      constituting Collateral for application to the Secured Obligations as
      provided in Article VIII hereof;

            (vi) Require each Issuer to execute and deliver to the Secured
      Parties an assignment of the Intellectual Property Collateral (the "IP
      Assignment"). Each Issuer hereby authorizes the Secured Parties to
      complete as Assignee and record with the United States Patent and
      Trademark Office and the United States Copyright Office each IP
      Assignment;

            (vii) Exercise any and all rights as beneficial and legal owner of
      the Collateral, including, without limitation, perfecting assignment of
      and exercising any and all consensual and other rights and powers with
      respect to any Collateral; and

            (viii) All the rights and remedies of a secured party on default
      under the UCC, and the Collateral Agent may also in its sole discretion,
      without notice except as specified in Section 9.2 hereof, sell, assign or
      grant a license to use the Collateral or any part thereof in one or more
      parcels at public or private sale, at any exchange, broker's board or at
      any of the Collateral Agent's offices or elsewhere, for cash, on credit or
      for future delivery, and at such price or prices and upon such other terms
      as the Collateral Agent may deem commercially reasonable. The Collateral
      Agent or any other Secured Party or any of their respective Affiliates may
      be the purchaser, licensee, assignee or recipient of any or all of the
      Collateral at any such sale and shall be entitled, for the purpose of
      bidding and making settlement or payment of the purchase price for all or
      any portion of the Collateral sold, assigned or licensed at such sale, to
      use and apply any of the Secured Obligations owed to such Person as a
      credit on account of the purchase price of any Collateral payable by such
      Person at such sale. Each purchaser, assignee, licensee or recipient at
      any such sale shall acquire the property sold, assigned or licensed
      absolutely free from any claim or right on the part of any Issuer, and
      each Issuer hereby waives, to the fullest extent permitted by law, all
      rights of redemption, stay and/or appraisal which it now has or may at any
      time in the future have under any rule of law or statute now existing or
      hereafter enacted. The Collateral Agent shall not be obligated to make any
      sale of Collateral regardless of notice of sale having been given. The
      Collateral Agent may adjourn any public or private sale from time to time
      by announcement at the time and place fixed therefor, and such sale may,
      without further notice, be made at the time and place to which it was so
      adjourned. Each Issuer hereby waives, to the fullest extent permitted by
      law, any claims against the Collateral Agent arising by reason of the fact
      that the price at which any Collateral may have been sold, assigned or
      licensed at such a private sale was

                                      -39-
<PAGE>
      less than the price which might have been obtained at a public sale, even
      if the Collateral Agent accepts the first offer received and does not
      offer such Collateral to more than one offeree.

            SECTION 9.2 Notice of Sale. Each Issuer acknowledges and agrees
that, to the extent notice of sale or other disposition of Collateral shall be
required by law, 10 days' prior notice to such Issuer of the time and place of
any public sale or of the time after which any private sale or other intended
disposition is to take place shall be commercially reasonable notification of
such matters. No notification need be given to any Issuer if it has signed,
after the occurrence of an Event of Default, a statement renouncing or modifying
any right to notification of sale or other intended disposition.

            SECTION 9.3 Waiver of Notice and Claims. Each Issuer hereby waives,
to the fullest extent permitted by applicable law, notice or judicial hearing in
connection with the Collateral Agent's taking possession or the Collateral
Agent's disposition of any of the Collateral, including, without limitation, any
and all prior notice and hearing for any prejudgment remedy or remedies and any
such right which such Issuer would otherwise have under law, and each Issuer
hereby further waives, to the fullest extent permitted by applicable law: (i)
all damages occasioned by such taking of possession, (ii) all other requirements
as to the time, place and terms of sale or other requirements with respect to
the enforcement of the Collateral Agent's rights hereunder and (iii) all rights
of redemption, appraisal, valuation, stay, extension or moratorium now or
hereafter in force under any applicable law. The Collateral Agent shall not be
liable for any incorrect or improper payment made pursuant to this Article IX in
the absence of gross negligence or willful misconduct. Any sale of, or the grant
of options to purchase, or any other realization upon, any Collateral shall
operate to divest all right, title, interest, claim and demand, either at law or
in equity, of any Issuer therein and thereto, and shall be a perpetual bar both
at law and in equity against any Issuer and against any and all Persons claiming
or attempting to claim the Collateral so sold, optioned or realized upon, or any
part thereof, from, through or under the Issuers.

            SECTION 9.4 Certain Sales of Collateral.

            (i)Each Issuer recognizes that, by reason of certain prohibitions
contained in law, rules, regulations or orders of any Governmental Authority,
the Collateral Agent may be compelled, with respect to any sale of all or any
part of the Collateral, to limit purchasers to those who meet the requirements
of such Governmental Authority. Each Issuer acknowledges that any such sales may
be at prices and on terms less favorable to the Collateral Agent than those
obtainable through a public sale without such restrictions, and, notwithstanding
such circumstances, agrees that any such restricted sale shall be deemed to have
been made in a commercially reasonable manner and that, except as may be
required by applicable law, the Collateral Agent shall have no obligation to
engage in public sales.

            (ii)Each Issuer recognizes that, by reason of certain prohibitions
contained in the Securities Act of 1933, as amended (the "Securities Act"), and
applicable state securities laws, the Collateral Agent may be compelled, with
respect to any sale of all or any part of the

                                      -40-
<PAGE>
Securities Collateral, to limit purchasers to Persons who will agree, among
other things, to acquire such Securities Collateral for their own account, for
investment and not with a view to the distribution or resale thereof. Each
Issuer acknowledges that any such private sales may be at prices and on terms
less favorable to the Collateral Agent than those obtainable through a public
sale without such restrictions (including, without limitation, a public offering
made pursuant to a registration statement under the Securities Act), and,
notwithstanding such circumstances, agrees that any such private sale shall be
deemed to have been made in a commercially reasonable manner and that the
Collateral Agent shall have no obligation to engage in public sales and no
obligation to delay the sale of any Securities Collateral for the period of time
necessary to permit the issuer thereof to register it for a form of public sale
requiring registration under the Securities Act or under applicable state
securities laws, even if such issuer would agree to do so.

            (iii) Notwithstanding the foregoing, each Issuer shall, upon the
occurrence and during the continuance of any Event of Default, at the reasonable
request of the Collateral Agent, for the benefit of the Collateral Agent, cause
any registration, qualification under or compliance with any Federal or state
securities law or laws to be effected with respect to all or any part of the
Securities Collateral as soon as practicable and at the sole cost and expense of
such Issuer. Each Issuer will use its commercially reasonable efforts to cause
such registration to be effected (and be kept effective) and will use its
commercially reasonable efforts to cause such qualification and compliance to be
effected (and be kept effective) as may be so requested and as would permit or
facilitate the sale and distribution of such Securities Collateral including,
without limitation, registration under the Securities Act (or any similar
statute then in effect), appropriate qualifications under applicable blue sky or
other state securities laws and appropriate compliance with all other
requirements of any Governmental Authority. Each Issuer shall use its
commercially reasonable efforts to cause the Collateral Agent to be kept advised
in writing as to the progress of each such registration, qualification or
compliance and as to the completion thereof, shall furnish to the Collateral
Agent such number of prospectuses, offering circulars or other documents
incident thereto as the Collateral Agent from time to time may request, and
shall indemnify and shall cause the issuer of the Securities Collateral to
indemnify the Collateral Agent and all others participating in the distribution
of such Securities Collateral against all claims, losses, damages and
liabilities caused by any untrue statement (or alleged untrue statement) of a
material fact contained therein (or in any related registration statement,
notification or the like) or by any omission (or alleged omission) to state
therein (or in any related registration statement, notification or the like) a
material fact required to be stated therein or necessary to make the statements
therein not misleading.

            (iv) If the Collateral Agent determines to exercise its right to
sell any or all of the Securities Collateral, upon written request, each Issuer
shall from time to time furnish to the Collateral Agent all such information as
the Collateral Agent may request in order to determine the number of securities
included in the Securities Collateral which may be sold by the Collateral Agent
as exempt transactions under the Securities Act and the rules of the Securities
and Exchange Commission thereunder, as the same are from time to time in effect.

            (v) Each Issuer further agrees that a breach of any of the covenants
contained in this Section 9.4 will cause irreparable injury to the Collateral
Agent and other Secured Parties,

                                      -41-
<PAGE>
that the Collateral Agent and the other Secured Parties have no adequate remedy
at law in respect of such breach and, as a consequence, that each and every
covenant contained in this Section 9.4 shall be specifically enforceable against
each Issuer, and each Issuer hereby waives and agrees not to assert any defenses
against an action for specific performance of such covenants except for a
defense that no Event of Default has occurred and is continuing.

            SECTION 9.5 No Waiver; Cumulative Remedies.

            (i) No failure on the part of the Collateral Agent to exercise, no
course of dealing with respect to, and no delay on the part of the Collateral
Agent in exercising, any right, power or remedy hereunder shall operate as a
waiver thereof; nor shall any single or partial exercise of any such right,
power or remedy hereunder preclude any other or further exercise thereof or the
exercise of any other right, power or remedy; nor shall the Collateral Agent be
required to look first to, enforce or exhaust any other security, collateral or
guaranties. The remedies herein provided are cumulative and are not exclusive of
any remedies provided by law.

            (ii) In the event that the Collateral Agent shall have instituted
any proceeding to enforce any right, power or remedy under this Agreement by
foreclosure, sale, entry or otherwise, and such proceeding shall have been
discontinued or abandoned for any reason or shall have been determined adversely
to the Collateral Agent, then and in every such case, each Issuer, the
Collateral Agent and each other Secured Party shall be restored to their
respective former positions and rights hereunder with respect to the Collateral,
and all rights, remedies and powers of the Collateral Agent and the other
Secured Parties shall continue as if no such proceeding had been instituted.

            SECTION 9.6 Certain Additional Actions Regarding Intellectual
Property. If any Event of Default shall have occurred and be continuing, upon
the written demand of Collateral Agent, each Issuer shall execute and deliver to
Collateral Agent an assignment or assignments of the registered Patents,
Trademarks and/or Copyrights related to the Collateral and such other documents
as are necessary or appropriate to carry out the intent and purposes hereof.
Within five Business Days of written notice thereafter from Collateral Agent,
each Issuer shall make available to Collateral Agent, to the extent within such
Issuer's power and authority, such personnel in such Issuer's employ on the date
of the Event of Default as Collateral Agent may reasonably designate to permit
such Issuer to continue, directly or indirectly, to produce, advertise and sell
the products and services sold by such Issuer under the registered Patents,
Trademarks and/or Copyrights related to the Collateral, and such persons shall
be available to perform their prior functions on Collateral Agent's behalf.

                                      -42-
<PAGE>
                                    ARTICLE X

                             APPLICATION OF PROCEEDS

            The proceeds received by the Collateral Agent in respect of any sale
of, collection from or other realization upon all or any part of the Collateral
pursuant to the exercise by the Collateral Agent of its remedies as a secured
creditor as provided in Article IX hereof shall be applied, together with any
other sums then held by the Collateral Agent in the manner set forth in the
Intercreditor Agreement.

                                   ARTICLE XI

                                  MISCELLANEOUS

            SECTION 11.1 Concerning the Collateral Agent.

            (i) The Collateral Agent has been appointed as collateral agent
pursuant to the Intercreditor Agreement. The actions of the Collateral Agent
hereunder are subject to the provisions of the Intercreditor Agreement. The
Collateral Agent shall have the right hereunder to make demands, to give
notices, to exercise or refrain from exercising any rights, and to take or
refrain from taking action (including, without limitation, the release or
substitution of the Collateral), in accordance with this Agreement and the
Intercreditor Agreement. The Collateral Agent may employ agents and
attorneys-in-fact in connection herewith and shall not be liable for the
negligence or misconduct of any such agents or attorneys-in-fact selected by it
in good faith. The Collateral Agent may resign and a successor Collateral Agent
may be appointed in the manner provided in the Intercreditor Agreement. Upon the
acceptance of any appointment as the Collateral Agent by a successor Collateral
Agent, that successor Collateral Agent shall thereupon succeed to and become
vested with all the rights, powers, privileges and duties of the retiring
Collateral Agent under this Agreement, and the retiring Collateral Agent shall
thereupon be discharged from its duties and obligations under this Agreement.
After any retiring Collateral Agent's resignation, the provisions hereof shall
inure to its benefit as to any actions taken or omitted to be taken by it under
this Agreement while it was the Collateral Agent.

            (ii) The Collateral Agent shall be deemed to have exercised
reasonable care in the custody and preservation of the Collateral in its
possession if such Collateral is accorded treatment substantially equivalent to
that which the Collateral Agent, in its individual capacity, accords its own
property consisting of similar instruments or interests, it being understood
that neither the Collateral Agent nor any of the Secured Parties shall have
responsibility for (i) ascertaining or taking action with respect to calls,
conversions, exchanges, maturities, tenders or other matters relating to any
Securities Collateral, whether or not the Collateral Agent or any other Secured
Party has or is deemed to have knowledge of such matters, or (ii) taking any
necessary steps to preserve rights against any Person with respect to any
Collateral.

                                      -43-
<PAGE>
            (iii) The Collateral Agent shall be entitled to rely upon any
written notice, statement, certificate, order or other document believed by it
to be genuine and correct and to have been signed, sent or made by the proper
person, and, with respect to all matters pertaining to this Agreement and its
duties hereunder, upon advice of counsel selected by it.

            (iv) If any item of Collateral also constitutes collateral granted
to Collateral Agent under any other deed of trust, mortgage, security agreement,
pledge or instrument of any type, in the event of any conflict between the
provisions hereof and the provisions of such other deed of trust, mortgage,
security agreement, pledge or instrument of any type in respect of such
collateral, the Collateral Agent, in its sole discretion, shall select which
provision or provisions shall control.

            SECTION 11.2 Collateral Agent May Perform; Collateral Agent
Appointed Attorney-in-Fact. If any Issuer shall fail to perform any covenants
contained in this Agreement (including, without limitation, any Issuer's
covenants to (i) pay the premiums in respect of all required insurance policies
hereunder, (ii) pay Charges, (iii) make repairs, (iv) discharge Liens or (v) pay
or perform any obligations of any Issuer under any Collateral) or if any
warranty on the part of any Issuer contained herein shall be breached, the
Collateral Agent may (but shall not be obligated to) do the same or cause it to
be done or remedy any such breach, and may expend funds for such purpose;
provided, however, that Collateral Agent shall in no event be bound to inquire
into the validity of any tax, lien, imposition or other obligation which any
Issuer fails to pay or perform as and when required hereby and which such Issuer
does not contest in accordance in accordance with the provision of Section 4.13
hereof. Any and all amounts so expended by the Collateral Agent shall be paid by
the Issuers in accordance with the provisions of Section 11.3 hereof. Neither
the provisions of this Section 11.2 nor any action taken by Collateral Agent
pursuant to the provisions of this Section 11.2 shall prevent any such failure
to observe any covenant contained in this Agreement nor any breach of warranty
form constituting an Event of Default. Each Issuer hereby appoints the
Collateral Agent its attorney-in-fact, with full authority in the place and
stead of such Issuer and in the name of such Issuer, or otherwise, from time to
time in the Collateral Agent's discretion to take any action and to execute any
instrument consistent with the terms of the Intercreditor Agreement and the
other collateral documents which the Collateral Agent may deem necessary or
advisable to accomplish the purposes hereof. The foregoing grant of authority is
a power of attorney coupled with an interest and such appointment shall be
irrevocable for the term hereof. Each Issuer hereby ratifies all that such
attorney shall lawfully do or cause to be done by virtue hereof.

            SECTION 11.3 Expenses. Each Issuer will upon demand pay to the
Collateral Agent the amount of any and all costs and expenses, including the
fees and expenses of its counsel and the fees and expenses of any experts and
agents which the Collateral Agent may incur in connection with (i) any action,
suit or other proceeding affecting the Collateral or any part thereof commenced,
in which action, suit or proceeding the Collateral Agent is made a party or
participates or in which the right to use the Collateral or any part thereof is
threatened, or in which it becomes necessary in the judgment of the Collateral
Agent to defend or uphold the Liens hereof (including, without limitation, any
action, suit or proceeding to establish or uphold the compliance of the
Collateral with any requirements of any Governmental Authority or law),

                                      -44-
<PAGE>
(ii) the collection of the Secured Obligations, (iii) the enforcement and
administration hereof, (iv) the custody or preservation of, or the sale of,
collection from, or other realization upon, any of the Collateral, (v) the
exercise or enforcement of any of the rights of the Collateral Agent or any
Secured Party hereunder or (vi) the failure by any Issuer to perform or observe
any of the provisions hereof. All amounts expended by the Collateral Agent and
payable by the Issuers under this Section 11.3 shall be due upon demand therefor
(together with interest thereon accruing at the highest rate then in effect
under the Purchase Agreements during the period from and including the date on
which such funds were so expended to the date of repayment) and shall be part of
the Secured Obligations. Each Issuer's obligations under this Section 11.3 shall
survive the termination hereof and the discharge of such Issuer's other
obligations under this Agreement, the Purchase Agreements and the other
collateral documents.

            SECTION 11.4 Indemnity.

            (i)Indemnity. Each Issuer agrees to indemnify, pay and hold harmless
the Collateral Agent and each of the other Secured Parties and the officers,
directors, employees, agents and Affiliates of the Collateral Agent and each of
the other Secured Parties (collectively, the "Indemnitees") from and against any
and all other liabilities, obligations, losses, damages, penalties, actions,
judgments, suits, claims, costs (including, without limitation, settlement
costs), expenses or disbursements of any kind or nature whatsoever (including,
without limitation, the reasonable fees and disbursements of counsel for such
Indemnitees in connection with any investigative, administrative or judicial
proceeding, commenced or threatened, whether or not such Indemnitee shall be
designated a party thereto) which may be imposed on, incurred by, or asserted
against that Indemnitee, in any manner relating to or arising out of this
Agreement, the Purchase Agreements, the Securities, the Preferred Stock, the
Certificate of Designation any other collateral document or any other document
evidencing the Secured Obligations (including, without limitation, any
misrepresentation by any Issuer in this Agreement, the Purchase Agreements, the
Securities, the Preferred Stock, other collateral document or any other document
evidencing the Secured Obligations) (the "Indemnified Liabilities"); provided,
however, that no Issuer shall have any obligation to an Indemnitee hereunder
with respect to Indemnified Liabilities if it has been determined by a final
decision (after all appeals and the expiration of time to appeal) of a court of
competent jurisdiction that such Indemnified Liabilities arose from the gross
negligence or willful misconduct of that Indemnitee. To the extent that the
undertaking to indemnify, pay and hold harmless set forth in the preceding
sentence may be unenforceable because it is violative of any law or public
policy, each Issuer shall contribute the maximum portion which it is permitted
to pay and satisfy under applicable law to the payment and satisfaction of all
Indemnified Liabilities incurred by the Indemnitees or any of them.

            (ii) Survival. The obligations of such Issuer's contained in this
Section 11.4 shall survive the termination hereof and the discharge of such
Issuer's other obligations under this Agreement, the Purchase Agreements and
under the other collateral documents.

            (iii) Reimbursement. Any amounts paid by any Indemnitee as to which
such Indemnitee has the right to reimbursement shall constitute Secured
Obligations secured by the Collateral.

                                      -45-
<PAGE>
            SECTION 11.5 Continuing Security Interests; Assignment. This
Agreement shall create a continuing security interest in the Collateral and
shall (i) be binding upon each Issuer, their respective successors and assigns
and (ii) inure, together with the rights and remedies of the Collateral Agent
hereunder, to the benefit of the Collateral Agent and the other Secured Parties
and each of their respective successors, transferees and assigns. No other
Persons (including, without limitation, any other creditor of the Issuers) shall
have any interest herein or any right or benefit with respect hereto. Without
limiting the generality of the foregoing clause (ii), any Secured Party may
assign or otherwise transfer any indebtedness held by it secured by this
Agreement to any other Person, and such other Person shall thereupon become
vested with all the benefits in respect thereof granted to such Secured Party,
herein or otherwise.

            SECTION 11.6 Termination; Release. The Collateral shall be released
from the Liens of this Agreement upon satisfaction in full of the Secured
Obligations relating to the Securities and the Vaniqa Collateral shall be
released from the Liens of this Agreement upon satisfaction in full of the
Secured Obligations relating to the Preferred Stock. Upon termination hereof or
any release of Collateral and/or Vaniqa Collateral, as the case may be, in
accordance with the foregoing, the Collateral Agent shall, upon the request and
at the sole cost and expense of the Issuers, assign, transfer and deliver to the
Issuers, against receipt and without recourse to or warranty by the Collateral
Agent, such of the Collateral and/or Vaniqa Collateral, as the case may be, to
be released (in the case of a release) as may be in possession of the Collateral
Agent and as shall not have been sold or otherwise applied pursuant to the terms
hereof, and, with respect to any other Collateral, proper documents and
instruments (including UCC-3 termination statements or releases) acknowledging
the termination hereof or the release of such Collateral and/or the Vaniqa
Collateral, as the case may be.

            SECTION 11.7 Modification in Writing. No amendment, modification,
supplement, termination or waiver of or to any provision hereof, nor consent to
any departure by the Issuers therefrom, shall be effective unless the same shall
be made in accordance with the terms of the Purchase Agreements and the
Certificate of Designation unless in writing and signed by the Collateral Agent.
Any amendment, modification or supplement of or to any provision hereof, any
waiver of any provision hereof and any consent to any departure by any Issuer
from the terms of any provision hereof shall be effective only in the specific
instance and for the specific purpose for which made or given. Except where
notice is specifically required by this Agreement or any other document
evidencing the Secured Obligations, no notice to or demand on any Issuer in any
case shall entitle such Issuer to any other or further notice or demand in
similar or other circumstances.

            SECTION 11.8 Notices. Unless otherwise provided herein or in the
Purchase Agreements, any notice or other communication herein required or
permitted to be given shall be given in the manner and become effective as set
forth in the Purchase Agreements, as to such Issuer, addressed to it at the
address of such Issuer set forth in the Purchase Agreements and as to the
Collateral Agent, addressed to it at the address set forth in the Intercreditor
Agreement, or in each case at such other address as shall be designated by such
party in a written notice to the other party complying as to delivery with the
terms of this Section 11.8.

                                      -46-
<PAGE>
            SECTION 11.9 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND
SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK.

            SECTION 11.10 CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER
OF JURY TRIAL. ALL JUDICIAL PROCEEDINGS BROUGHT AGAINST THE ISSUERS WITH RESPECT
TO THIS AGREEMENT MAY BE BROUGHT IN THE SUPREME COURT OF THE STATE OF NEW YORK
SITTING IN NEW YORK COUNTY, THE COURTS OF THE UNITED STATES OF AMERICA FOR THE
SOUTHERN DISTRICT OF NEW YORK AND APPELLATE COURTS OF ANY THEREOF, AND BY
EXECUTION AND DELIVERY HEREOF, EACH ISSUER ACCEPTS FOR ITSELF AND IN CONNECTION
WITH ITS PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE
JURISDICTION OF THE AFORESAID COURTS AND IRREVOCABLY AGREES TO BE BOUND BY ANY
JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT. EACH ISSUER AGREES
THAT SERVICE OF PROCESS IN ANY PROCEEDING MAY BE EFFECTED BY MAILING A COPY
THEREOF BY REGISTERED OR CERTIFIED MAIL (OR ANY SUBSTANTIALLY SIMILAR FORM OF
MAIL), POSTAGE PREPAID, TO SUCH ISSUER AT ITS ADDRESS SET FORTH IN THE PURCHASE
AGREEMENTS OR AT SUCH OTHER ADDRESS OF WHICH THE COLLATERAL AGENT SHALL HAVE
BEEN NOTIFIED PURSUANT THERETO. IF ANY AGENT APPOINTED BYANY ISSUER REFUSES TO
ACCEPT SERVICE, SUCH ISSUER HEREBY AGREES THAT SERVICE UPON IT BY MAIL SHALL
CONSTITUTE SUFFICIENT NOTICE. NOTHING HEREIN SHALL AFFECT THE RIGHT TO SERVE
PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR SHALL LIMIT THE RIGHT OF THE
COLLATERAL AGENT TO BRING PROCEEDINGS AGAINST EACH ISSUER IN THE COURTS OF ANY
OTHER JURISDICTION. EACH ISSUER HEREBY IRREVOCABLY WAIVE ALL RIGHT TO A TRIAL BY
JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO
THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

            SECTION 11.11 Severability of Provisions. Any provision hereof which
is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or
unenforceability without invalidating the remaining provisions hereof or
affecting the validity or enforceability of such provision in any other
jurisdiction.

            SECTION 11.12 Execution in Counterparts. This Agreement and any
amendments, waivers, consents or supplements hereto may be executed in any
number of counterparts and by different parties hereto in separate counterparts,
each of which when so executed and delivered shall be deemed to be an original,
but all such counterparts together shall constitute one and the same agreement.

            SECTION 11.13 Business Days. In the event any time period or any
date provided in this Agreement ends or falls on a day other than a Business
Day, then such time period shall be deemed to end and such date shall be deemed
to fall on the next succeeding Business

                                      -47-
<PAGE>
Day, and performance herein may be made on such Business Day, with the same
force and effect as if made on such other day.

            SECTION 11.14 No Credit for Payment of Taxes or Imposition. No
Issuer shall be entitled to any credit against the principal, premium, if any,
or interest payable under the Security Purchase Agreement or the Securities, or
any liquidation preference or dividends under the Preferred Stock Purchase
Agreement or the Preferred Stock, and no Issuer shall be entitled to any credit
against any other sums which may become payable under the terms thereof or
hereof, by reason of the payment of any Tax on the Collateral or any part
thereof.

            SECTION 11.15 No Claims Against Collateral Agent. Nothing contained
in this Agreement shall constitute any consent or request by the Collateral
Agent, express or implied, for the performance of any labor or services or the
furnishing of any materials or other property in respect of the Collateral or
any part thereof, nor as giving any Issuer any right, power or authority to
contract for or permit the performance of any labor or services or the
furnishing of any materials or other property in such fashion as would permit
the making of any claim against the Collateral Agent in respect thereof or any
claim that any Lien based on the performance of such labor or services or the
furnishing of any such materials or other property is prior to the Liens hereof.

            SECTION 11.16 Obligations Absolute. All obligations of the Issuers
hereunder shall be absolute and unconditional irrespective of:

            (i) any bankruptcy, insolvency, reorganization, arrangement,
      readjustment, composition, liquidation or the like of any Issuer;

            (ii) any lack of validity or enforceability of the Purchase
      Agreements, the Securities, the Preferred Stock or any other collateral
      document, or any other agreement or instrument relating thereto;

            (iii)any change in the time, manner or place of payment of, or in
      any other term of, all or any of the Secured Obligations, or any other
      amendment or waiver of or any consent to any departure from the Purchase
      Agreements, the Securities, the Preferred Stock or any other collateral
      document, or any other agreement or instrument relating thereto;

            (iv) any pledge, exchange, release or non-perfection of any other
      collateral, or any release or amendment or waiver of or consent to any
      departure from any guarantee, for all or any of the Secured Obligations;

            (v) any exercise, non-exercise or waiver of any right, remedy, power
      or privilege under or in respect hereof, the Purchase Agreements, the
      Securities, the Preferred Stock or any other collateral document except as
      specifically set forth in a waiver granted pursuant to the provisions of
      Section 11.7 hereof; or

                                      -48-
<PAGE>
            (vi) any other circumstances which might otherwise constitute a
      defense available to, or a discharge of, any Issuer.

                [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

                                      -49-
<PAGE>
            IN WITNESS WHEREOF, the Issuers and the Collateral Agent have caused
this Agreement to be duly executed and delivered by their duly authorized
officers as of the date first above written.

                                 WOMEN FIRST HEALTHCARE, INC.

                                 By:      /s/ Charles M. Caporale
                                    ---------------------------------------
                                       Name:    Charles M. Caporale
                                       Title:   Vice President, Chief Financial
                                                Officer, Treasurer and Secretary

                                 AS WE CHANGE, L.L.C.

                                 By:      /s/ Charles M. Caporale
                                    ---------------------------------------
                                       Name:    Charles M. Caporale
                                       Title:   Vice President, Chief Financial
                                                Officer, Treasurer and Secretary

                                 CIBC WMC INC.,
                                       as Collateral Agent
                                 By:      /s/ William P. Phoenix
                                    ---------------------------------------
                                       Name:    William P. Phoenix
                                       Title:   Managing Director<PAGE>

                                                                   EXHIBIT 10.35

                                 PROMISSORY NOTE
                                DECEMBER 30, 2002

FOR VALUE RECEIVED, LA JOLLA PHARMACEUTICAL COMPANY a corporation located at the
address stated below ("MAKER") promises, jointly and severally if more than one,
to pay to the order of GENERAL ELECTRIC CAPITAL CORPORATION or any subsequent
holder hereof (each, a "PAYEE") at its office located at 401 MERRITT 7 SUITE 23,
NORWALK, CT 06851-1177 or at such other place as Payee or the holder hereof may
designate, the principal sum of SIX HUNDRED NINETY SEVEN THOUSAND SIX HUNDRED
FOUR AND 85/100 DOLLARS ($697,604.85), with interest on the unpaid principal
balance, from the date hereof through and including the dates of payment, at a
fixed interest rate of Nine and Seventy Hundreths percent (9.70%) per annum, to
be paid in lawful money of the United States, in Fourty Two (42) consecutive
monthly installments of principal and interest as follows:

<TABLE>
<CAPTION>
   Periodic
  Installment                Amount
  -----------                ------
<S>                        <C>
Thirty-Six (36)            $20,388.38
Five (5)                   $13,143.27
</TABLE>

each ("Periodic Installment") and a final installment which shall be in the
amount of the total outstanding principal and interest. The first Periodic
Installment shall be due and payable on January 1, 2003 and the following
Periodic Installments and the final installment shall be due and payable on the
same day of each succeeding month (each, a "Payment Date"). Such installments
have been calculated on the basis of a 360 day year of twelve 30-day months.
Each payment may, at the option of the Payee, be calculated and applied on an
assumption that such payment would be made on its due date.

The acceptance by Payee of any payment which is less than payment in full of all
amounts due and owing at such time shall not constitute a waiver of Payee's
right to receive payment in full at such time or at any prior or subsequent
time.

The Maker hereby expressly authorizes the Payee to insert the date value is
actually given in the blank space on the face hereof and on all related
documents pertaining hereto.

This Note may be secured by a security agreement, chattel mortgage, pledge
agreement or like instrument (each of which is hereinafter called a "SECURITY
AGREEMENT").

Time is of the essence hereof. If any installment or any other sum due under
this Note or any Security Agreement is not received within ten (10) days after
its due date, the Maker agrees to pay, in addition to the amount of each such
installment or other sum, a late payment charge of five percent (5%) of the
amount of said installment or other sum, but not exceeding any lawful maximum.
If (i) Maker fails to make payment of any amount due hereunder within ten (10)
days after the same becomes due and payable; or (ii) Maker is in default under,
or fails to perform under any term or condition contained in any Security
Agreement, then the entire principal sum remaining unpaid, together with all
accrued interest thereon and any other sum payable under this Note or any
Security Agreement, at the election of Payee, shall immediately become due and
payable, with interest thereon at the lesser of eighteen percent (18%) per annum
or the highest rate not prohibited by applicable law from the date of such
accelerated maturity until paid (both before and after any judgment).

Notwithstanding anything to tire contrary contained herein or in the Security
Agreement, Maker may not prepay in full or in part any indebtedness hereunder
without the express written consent of Payee in its sole discretion.

It is the intention of the parties hereto to comply with the applicable usury
laws; accordingly, it is agreed that, notwithstanding any provision to the
contrary in this Note or any Security Agreement, in no event shall this Note or
any Security Agreement require the payment or permit the collection of interest
in excess of the maximum amount permitted by applicable law. If any such excess
interest is contracted for, charged or received under this Note or any Security
Agreement, or if all of the principal balance shall be prepaid, so that under
any of such circumstances the amount of interest contracted for, charged or
received under this Note or any Security Agreement on the principal balance
shall exceed the maximum amount of interest permitted by applicable law, then in
such event (a) the provisions of this paragraph shall govern and control, (b)
neither Maker nor any other person or entity now or hereafter

<PAGE>

liable for the payment hereof shall be obligated to pay the amount of such
interest to the extent that it is in excess of the maximum amount of interest
permitted by applicable law, (c) any such excess which may have been collected
shall be either applied as a credit against the then unpaid principal balance or
refunded to Maker, at the option of the Payee, and (d) the effective rate of
interest shall be automatically reduced to the maximum lawful contract rate
allowed under applicable law as now or hereafter construed by the courts having
jurisdiction thereof. It is further agreed that without limitation of the
foregoing, all calculations of the rate of interest contracted for charged or
received under this Note or any Security Agreement which are made for the
purpose of determining whether such rate exceeds the maximum lawful contract
rate, shall be made, to the extent permitted by applicable law, by amortizing,
prorating, allocating and spreading in equal parts during the period of the full
stated term of the indebtedness evidenced hereby, all interest at any time
contracted for, charged or received from Maker or otherwise by Payee in
connection with such indebtedness; provided, however, that if any applicable
state law is amended or the law of the United States of America preempts any
applicable state law, so that it becomes lawful for the Payee to receive a
greater interest per annum rate than is presently allowed, the Maker agrees
that, on the effective date of such amendment or preemption, as the case may be,
the lawful maximum hereunder shall be increased to the maximum interest per
annum rate allowed by the amended state law or the law of the United States of
America.

The Maker and all sureties, endorsers, guarantors or any others (each such
person, other than the Maker, an "OBLIGOR") who may at any time become liable
for the payment hereof jointly and severally consent hereby to any and all
extensions of time, renewals, waivers or modifications of, and all substitutions
or releases of, security or of any party primarily or secondarily liable on this
Note or any Security Agreement or any term and provision of either, which may be
made granted or consented to by Payee, and agree that suit may be brought and
maintained against any one or more of them, at the election of Payee without
joinder of any other as a party thereto, and that Payee shall not be required
first to foreclose, proceed against, or exhaust any security hereof in order to
enforce payment of this Note. The Maker and each Obligor hereby waives
presentment, demand for payment, notice of nonpayment, protest, notice of
protest, notice of dishonor, and all other notices in connection herewith, as
well as filing of suit (if permitted by law) and diligence in collecting this
Note or enforcing any of the security hereof, and agrees to pay (if permitted by
law) all expenses incurred in collection, including Payee's actual attorneys'
fees. Maker and each Obligor agrees that fees not in excess of twenty percent
(20%) of the amount then due shall be deemed reasonable.

THE MAKER HEREBY UNCONDITIONALLY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM
OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF, DIRECTLY OR INDIRECTLY, THIS
NOTE, ANY OF THE RELATED DOCUMENTS, ANY DEALINGS BETWEEN MAKER AND PAYEE
RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS,
AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN MAKER AND PAYEE. THE
SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES
THAT MAY BE FILED IN ANY COURT (INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS,
TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY
CLAIMS.) THIS WAIVER IS IRREVOCABLE MEANING THAT IT MAY NOT BE MODIFIED EITHER
ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS,
RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE, ANY RELATED DOCUMENTS, OR
TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED
TRANSACTION. IN THE EVENT OF LITIGATION, THIS NOTE MAY BE FILED AS A WRITTEN
CONSENT TO A TRIAL BY THE COURT.

This Note and any Security Agreement constitute the entire agreement of the
Maker and Payee with respect to the subject matter hereof and supercedes all
prior understandings, agreements and representations, express or implied.

No variation or modification of this Note, or any waiver of any of its
provisions or conditions, shall be valid unless in writing and signed by an
authorized representative of Maker and Payee. Any such waiver, consent,
modification or change shall be effective only in the specific instance and for
the specific purpose given.

<PAGE>

Any provision in this Note or any Security Agreement which is in conflict with
any statute, law or applicable rule shall be deemed omitted, modified or altered
to conform thereto.

                                           LA JOLLA PHARMACEUTICAL COMPANY

/s/ Lisa Peraza                            By: /s/ Gail A. Sloan
---------------------------                    ---------------------------------
Lisa Peraza (Witness)                         Gail A. Sloan
6455 Nancy Ridge Drive                        Senior Director of Finance
San Diego, CA 92121                           and Controller

                                              Federal Tax ID #: 330361285
                                              Address: 6455 Nancy Ridge Drive
                                              San Diego, CA 92121

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]